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1. Summary 
The studies of this thesis gave us a unique opportunity to analyse the state of epidermal and 
epithelial barrier in the context of several allergic diseases, and find unique avenues of 
interaction between microbiota of epithelial surfaces and epithelial barrier. We performed 
RNA-sequencing of lesional and non-lesional skin of atopic dermatitis patients and compared 
AD skin transcriptome to the skin transcriptome of healthy subjects. We focussed on the 
regulation of tight junctions in AD lesions, as well as the regulation of other cell-cell junction 
molecules such as adherens junctions, gap junctions, desmosomes and stratum corneum 
proteins. We observed the severe downregulation of the majority of junctional molecules in 
lesional AD skin, in comparison to non-lesional AD skin and healthy skin. To complement the 
RNA-seq analysis of AD skin, we also performed 16S ribosomal DNA sequencing of the skin 
swabs of same patients with AD, to profile the lesional and non-lesional skin microbiota of AD 
individuals. We observed the increased frequency and abundance of Staphylococcus species in 
lesional AD skin, foremost among them Staphylococcus aureus. We also observed the negative 
correlation of S. aureus frequency with other commensal bacteria of the skin, such as 
Staphylococcus epidermidis in lesional skin of AD patients. Furthermore; the matched data we 
acquired from transcriptome and microbiome gave us the unique opportunity to combine and 
analyse different “-omics” data-sets together. We correlated a gene set consisting of different 
gene families corresponding to cellular junctions such as tight junctions, adherens junctions, 
gap junctions, desmosomes and stratum corneum molecules to the most abundant 
Staphylococcus species found in AD skin. As a result of this study, we identified significant 
correlations across multiple bacterial species in 4 tight junction molecules: Claudin-4, claudin-
5, zo-1 (TJP-1) and zo-2 (TJP-2). These 4 tight junction molecules show negative correlation 
with S. aureus abundance and show positive correlation with commensal species of the skin, 
S. epidermidis, S. hominis, S. haemolyticus and S. caprae. The mechanism of possible 
5 
 
interaction between tight junction expression and microbial colonization is currently unknown, 
but our data suggests a link between increased colonization of AD lesions with S. aureus is 
partly due to decreased tight junction expression and disruption of the skin barrier. 
In the second study, we focussed of the tissue responses to the changes in microbiota in the 
context of another allergic disease, chronic rhinosinusitis (CRS). Tissue explants from inferior 
turbinate area of nasal epithelium or nasal polyps were stimulated in vitro with S. aureus or S. 
epidermidis. We analysed the expression changes on a series of TJ molecules, and observed 
the increased expression of multiple TJ molecules in response to S. aureus and S. epidermidis 
in healthy nasal tissue. This observation showed us that healthy epithelium is indeed capable 
of responding to introduction of pathogens onto epithelial surface, and upregulates or closes 
barrier in response to threats. On the other hand, nasal polyp tissue from CRS patients showed 
no change or downregulation of the epithelial barrier molecules in response to S. aureus 
stimulation.  
Our third study investigated the changes in epidermal barrier in the context of contact 
dermatitis. Skin of hairdressers allergic to the contact allergen p-phenylenediamine (PPD) 
commonly found in hair dye products were stimulated with PPD and RNA-seq was performed 
on skin biopsies. For the first time, we analysed the state of epidermal barrier in contact 
dermatitis and identified the extensive downregulation of TJ molecules both in terms of mRNA 
expression and protein localization. Surprisingly, skin of PPD allergic individuals before PPD 
contact showed no indication of barrier disruption and changes in TJ gene expression 
suggesting the importance of allergen exposure, immune response and the subsequent 
inflammation to the barrier disruption in allergic skin diseases.   
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The results described in this thesis give new insight into the state and regulation of epithelial 
barrier in several allergic diseases and into the intricate interactions between microbiota and 
epithelial barrier. 
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2. Zusammenfassung 
Die Studien dieser Arbeit gaben uns eine einzigartige Möglichkeit den Status der 
epidermalen und epithelialen Barriere im Zusammenhang mit verschiedenen allergischen 
Erkrankungen zu analysieren und Zusammenhänge der Interaktion zwischen Mikrobiota 
der Epitheloberflächen und der Epithelbarriere zu finden. Wir führten RNA-Sequenzierung 
(RNA-seq) von läsionaler und nicht-läsionaler Haut von Patienten mit atopischer 
Dermatitis (AD) durch und verglichen das AD-Hauttranskriptom mit dem 
Hauttranskriptom von gesunden Probanden. Der Schwerpunkt dabei lag sowohl auf der 
Untersuchung der Regulation von Tight Junctions (TJ) in AD-Läsionen als auch anderer 
Zell-Zell-Verbindungs-Moleküle, wie Adherens Junctions, Gap Junctions, Desmosomen 
und Proteine des Stratum Corneums. Wie schon in vorangegangenen Studien konnten wir 
eine starke Herabregulierung der Mehrzahl von junktionalen Molekülen in läsionaler Haut 
von AD Patienten im Vergleich zu nicht-läsionaler AD-Haut und gesunder Haut 
beobachten. Die RNA-seq Analysen vervollständigten wir durch eine 16S DNA 
Sequenzierung der gleichen AD-Patienten, um ein Profil des Mikrobioms von läsionaler 
und nicht-läsionaler Haut zu erstellen. Durch diese Analyse konnten wir eine erhöhte 
Frequenz und Häufigkeit von Staphylococcus-Arten in läsionaler AD Haut erkennen, in 
erster Linie Staphylococcus aureus. Ferner konnten wir eine negative Korrelation von S. 
aureus mit anderen symbiotischen Bakterien, wie Staphylococcus epidermidis, in der 
läsionalen Haut von AD Patienten feststellen. Die dadurch gewonnenen Daten von 
Transkriptom und Mikrobiom erlaubten uns die Kombination und Analyse von 
verschiedenen        «-omics» Datensätze. Dadurch konnten wir ein Set von Genen aus 
verschiedenen Genfamilien der Zellverbindungen, wie Adherens Junctions, Gap Junctions, 
Desmosomen und Stratum Corneum mit den häufigsten Staphylococcus-Arten in der Haut 
von AD Patienten korrelieren. In diesem Kontext konnten wir signifikante Korrelationen 
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zwischen Bakterienarten in den vier TJ-Molekülen, Claudin-4, Claudin-5, ZO-1 (TJP-1) 
und ZO-2 (TJP-2), identifizieren. Diese vier TJ-Moleküle zeigen eine negative Korrelation 
zur S. aureus Abundanz und eine positive Korrelation mit symbiotischen Spezies der Haut, 
wie S. epidermidis, S. hominus, S. haemolyticus und S. caprae. Der Mechanismus 
möglicher Wechselwirkungen zwischen Tight-Junction-Expression und mikrobieller 
Kolonisation ist derzeit unbekannt, wir postulierten jedoch, dass die erhöhte Kolonisierung 
von AD-Läsionen mit S. aureus teilweise auf eine verminderte Tight-Junction-Expression 
und eine Störung der Hautbarriere zurückzuführen ist. 
In der zweiten Studie konzentrierten wir uns auf die Gewebereaktionen durch 
Veränderungen der Mikrobiota im Zusammenhang mit einer anderen allergischen 
Erkrankung, der chronischen Rhinosinusitis (CRS). Gewebeexplantate aus dem unteren 
Nasenmuschelbereich des Nasenepithels oder Nasenpolypen wurden in vitro mit S. aureus 
oder S. epidermidis stimuliert. Wir analysierten die Expressionsänderungen einer Reihe 
von TJ-Molekülen und beobachteten die erhöhte Expression von multiplen TJ-Molekülen 
als Antwort auf S. aureus und S. epidermidis in gesundem Nasengewebe. Diese 
Beobachtung zeigte uns, dass gesundes Epithel in der Tat in der Lage ist, auf die Co-
Kultivierung von Pathogenen auf die Epitheloberfläche zu reagieren und die Barriere als 
Reaktion auf Bedrohungen hochreguliert oder schließt. Auf der anderen Seite zeigten 
Nasenpolypengewebe von CRS-Patienten keine Veränderung oder Herabregulierung als 
Reaktion auf die Stimulation mit S. aureus. 
In der dritten Studie untersuchten wir Veränderungen der epidermalen Barriere im 
Zusammenhang mit Kontaktdermatitis. Haut von Friseuren, die gegen das Kontaktallergen 
p-Phenylendiamin (PPD) allergisch sind, das allgemein in Haarfärbeprodukten gefunden 
wird, wurde mit PPD stimuliert und RNA-seq wurde an Hautbiopsien durchgeführt. Zum 
ersten Mal analysierten wir den Zustand der epidermalen Barriere bei Kontaktdermatitis 
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und identifizierten die umfangreiche Herunterregulation von TJ-Molekülen sowohl in 
Bezug auf die mRNA-Expression als auch auf die Proteinlokalisierung. 
Überraschenderweise zeigte die Haut von PPD-Allergikern vor PPD-Kontakt keinen 
Hinweis auf eine Barrierestörung und Veränderungen in der TJ-Genexpression, was uns 
die Bedeutung der Präsenz von Allergenen und der anschließenden Entzündung bis zur 
Barrierestörung bei allergischen Hauterkrankungen verdeutlicht. 
Die in dieser Arbeit beschriebenen Ergebnisse geben neue Einblicke in den Zustand der 
epithelialen Barriere bei verschiedenen allergischen Erkrankungen und in die komplexen 
Wechselwirkungen zwischen Mikrobiota und Epithelbarriere. 
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3. Abbreviations 
AD: Atopic Dermatitis 
FLG: Filaggrin  
TEWL: Transepidermal water loss  
IgE : Immunoglobulin E 
S. aureus : Staphylococcus Aureus 
IL: Interleukin 
RANTES: Regulated on activation, normal T cell expressed and secreted 
APOC1: Apolipoprotein 1  
ZO: Zonula Occludens  
SC: Stratum corneum 
PRR: Pattern recognition receptor  
TLR: Toll-like receptor  
LPS: Lipopolysaccharide  
AMP: Anti-microbial peptide  
TNF: Tumor necrosis factor  
TGF: Transforming growth factor  
CSF: Colony stimulating factor  
GM-CSF: Granulocyte colony stimulating factor 
TJ: Tight junction 
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TJP: Tight junction protein  
CCL: CC chemokine ligand   
CXCL:  CXC chemokine ligand  
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4. General Introduction 
4.1. Definition and general outline of AD 
Atopic dermatitis (AD) is a chronic, pruritic inflammatory disease most with a considerable 
impact on the quality of life of patients suffering from the disease. Hallmarks of AD are itchy, 
dry and cracked skin, usually confined to certain areas like hands, insides of elbows, neck and 
chest. The “atopic” component of the disease means AD patients are usually sensitized against 
one or more allergens, most commonly grass and tree pollen, house dust mite, or food allergens 
like cow milk, peanut, egg, wheat or seafood. Exposure to the allergen, alongside various other 
irritant environmental factors like cold air or hard soap triggers “flare-ups” on the exposed 
regions of the skin. These AD lesions display erythema, skin edema, papules and itchiness. 
Lesions usually heal up in 1-3 weeks on their own, but flare-ups can repeat with scratching or 
further exposure to allergen. Bacterial infections of the lesions are commonly encountered, 
main culprit being Staphylococcus aureus (S. aureus). It is now thought that AD has multiple 
endotypes with a large (25%-30%) of patients lacking Immunoglobulin E (IgE) mediated 
sensitization. 1, 2 A further 10%-40% of cases display genetic susceptibility to AD in the form 
of function-loss mutations for epidermal barrier proteins such as filaggrin (FLG) or genes of 
immunologic function, such as Interleukin 4 (IL4), IL5, IL13 and regulated on activation, 
normal T cell expressed and secreted (RANTES).3 
AD is more commonly seen in developed and industrialized countries as part of the allergy 
epidemic, with AD prevalence increasing by 50%-80% in the last 30 years. AD is also 
encountered more commonly and with increased severity in regions with cold and dry air, such 
as North America, Northern Europe and Scandinavia. 4 AD is mainly a childhood disease, with 
about 60% of the patients outgrowing the disease with puberty. However, the remaining 40% 
of cases that continue to have AD in adulthood are more likely to have severe disease 
symptoms. 5 
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Treatment options include identification and elimination of irritant factors; such as S. aureus 
with anti-microbial soaps 6. Eradication of aeroallergens or contact allergens from the patients 
living space is also known to decrease disease severity 7. Skin hydration is one of the most 
commonly used measures to maintain normal barrier function, decrease the transepidermal 
water loss (TEWL) and reduce colonization by skin pathogens like S. aureus 8. Apart from 
these options, topical corticosteroids have been the best option for reducing inflammation, 
pruritus and resolve lesional skin symptoms 9, 10.  
4.2. Epidermal barrier in the context of skin diseases 
Previous studies have demonstrated that the barrier loss is already present in non-lesional skin, 
with a more significant impairment observed in lesional AD skin compared to healthy controls 
11. This disturbed barrier in AD is thought to allow infiltration of allergens and pathogens into 
the skin, like house dust mite, pollen and cat dander allergens, which begin the cycle of 
inflammation and lesion formation. The link between TEWL and allergen sensitization have 
been observed to support this hypothesis 12. 
So far, the barrier studies in the context of AD have focused on state of skin lipid barrier and 
the state of stratum corneum (SC) in AD. Skin surface lipids have been reported to be 
significantly lower in abundance in comparison to healthy individuals 13, 14. AD individuals 
display an overall decrease in epidermal lipids and a significant decrease in ceramides in 
lesional skin 15, 16. However, the overall percentage of triglycerides, phospholipids, free fatty 
acids and cholesterol derivatives do not change significantly in lesional and non-lesional AD 
skin 17. Furthermore; mice with Apolipoprotein 1 (APOC1) overexpression in skin display an 
AD-like skin phenotype with increased TEWL, scaling, lichenification and pruritus, all 
indicative of a disturbed skin barrier. APOC1 mice also display increased serum IgE and IgE(+) 
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mast cells, as well as epidermal thickening and immune cell infiltration into skin, in support of 
sensitization hypothesis in the absence of skin barrier 18. 
Genetic defects of the epidermal barrier have long been known as one of the major factors as a 
proponent of AD. The first sign was the observance of reduced FLG expression in non-lesional 
and lesional skin of AD patients 19. Then, many groups and investigators found highly 
significant increase in mutations and SNPs, including deletion and cleaving mutations in 
patients with AD and ichthyosis vulgaris 20-23. Loss of function genetic variants in the sequence 
of FLG; such as R510X and 2282del4 have been described in association with AD comorbidity 
with asthma 20. It is now known that FLG mutations are present in about 10% of European 
population and AD cases include 20%-40% mutations in the FLG gene. 
FLG is responsible for the water binding capabilities of skin 24. FLG is also responsible for 
aggregation of keratin filaments in corneocytes, and directly assists the flattening of 
corneocytes and formation of SC 20. Loss of function polymorphisms in FLG gene are also 
implicated in a wide variety of eczematous skin diseases, including irritant contact dermatitis 
25 , allergic contact dermatitis with nickel allergen 26 and hand eczema. Mouse models that 
knock-down FLG typically display AD or ichthyosis-like skin with dry, flaky skin such as the 
flaky tail mouse, which demonstrates the importance of FLG in skin homeostasis 27, 28 . 
Genetic impairment of epidermal barrier in AD is not only limited to the FLG gene. Small 
proline rich-proteins, S100A anti-bacterial peptides, late cornified proteins and various skin 
junction molecules have all been described as having genetic polymorphisms in various patient 
groups with AD 29. 
4.3.Tight junctions of the skin 
The most integral part of the physical barrier of the epithelial layer is the tight junctions (TJ) 
that seal the intercellular spaces between adjacent epithelial cells 30, 31. TJ are also responsible 
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of maintaining monolayer structure and tissue function of epithelial layer by connecting cell-
cell junction formations to cytoskeletal elements 32, 33. 
Claudin family is the largest set of transmembrane proteins making up the TJ barrier, with 27 
genes enocoded in human genome 34. Claudin family molecules are divided into maintaining 
two different functions: Claudins, CLDN1, CLDN4, CLDN5 and CLDN10 are responsible for 
maintaining the sealed barrier between adjacent cells and regulating paracellular flux between 
outer tissue and inner tissue environments. Channel forming claudins such as CLDN2, CLDN3, 
CLDN21 and CLDN22 regulated the permeability of epithelial barrier to ions, water and small 
charged molecules 35-37. 
Occludin, Tricellulin ( MARVELD2) and MARVELD3 are TJ molecules that are expressed at 
the connection points of three or more cells. These molecules are not sufficient to maintain 
epithelial barrier; but are thought to be important for maintaining epithelial layer structure and 
apical-basolateral orientation of cells 38, 39.  
Tight junction protein 1(TJP1), TJP2 and TJP3, otherwise known as Zonula Occludens (ZO) 
family are TJ proteins that have neither sealing, nor channel forming function. Instead, they 
are adaptor molecules that constitute the signalling part of TJ complexes. TJP molecules are 
essential for claudin localization to the apical membrane regions of epithelial cells 40, 41. 
4.4.Role of Innate Immunity in pathogenesis of AD 
Pattern recognition receptors (PRRs) are crucial for recognition of invading pathogens by tissue 
cells and immune cells. As skin is the largest organ open to outside intrusion; PRRs constitute 
one of the first defence mechanisms against bacteria, fungi, viruses, as well as allergens and 
pollutants. PRRs are found on both cell surface, where they are capable of activating upon 
recognizing extracellular threats, or are found intracellularly, for recognition of viral and 
intracellular bacterial intrusions 42-44.  
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PRRs such as Toll-like receptor (TLR1), TLR2, and TLR6 recognize bacterial lipopeptides, 
TLR2 is capable of activation upon bacterial cell wall components such as peptidoglycans. 
TLR4 recognizes bacterial lipopolysaccharides (LPS), and TLR5 binds to bacterial mobility 
molecules such as flagellin. The ligand for TLR11 profilin, which is found in most plant origin 
allergens, such as birch or grass pollen.  
Intracellular TLRs are more tailored towards recognizing viral threats. TLR3 is activated upon 
dsRNA binding, and TLR7 recognizes ssRNA fragments. Finally, TLR8 and TLR9 recognize 
free nucleic acids in cell compartments, which are normally confined to nuclei and released 
only upon tissue damage and cell death 45. 
Most TLRs signal through the adaptor molecules MyD88, TRAP or TRIF. Activation of 
TLR/MyD88 pathways results in activation of MAPK kinase cascade and NfKB, and leads to 
transcription of mainly pro-inflammatory cytokines such as IL1α, IL1β, Tumor growth factor 
alpha (TNFα), IL6 and IL12 46. 
Polymorphisms of various TLR molecules have been reported in AD. Excessive function 
mutations such as TLR2 R753Q is thought to result in overexpression of IL6 and IL12, thus 
contributing to the inflammatory cycle in AD lesions 47. Whereas downregulation of CD14 
associated with TLR4 might result in decreased response to bacterial pathogens in AD skin and 
increase S. aureus frequency in AD patients 48. 
Anti-microbial peptides (AMP) are also an effective defence system utilized by keratinocytes 
for direct killing of microbes and prevent excessive colonization. Defensins such as Human 
Beta Defensin (HBD1), HBD2, HBD3 and HBD4 are expressed in keratinocytes and can be 
activated by a wide variety of factors such as presence of pro-inflammatory cytokines, changes 
in skin pH levels, bacterial infection and epithelial cell differentiation. Defensins show direct 
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killing activity against Gram-negative and Gram-positive bacteria, as well as fungi and viruses 
49, 50. 
Cathelicidins act like alarmin molecules that also have microbe killing function. Cathelicidins 
are capable of binding to negative charge bacterial membranes and increase permeability of 
bacterial cell wall. As an alarmin function, cathelicidins such as LL37 are capable of engaging 
a variety of cellular receptors; mainly G-coupled protein receptors and growth factor receptors 
to trigger pro-inflammatory cytokine secretion and keratinocyte proliferation. IL6, IL10, 
interferon gamma-induced protein 10 (IP10), monocyte chemotactic protein 1 (MCP1), 
macrophage inflammatory protein 1-alpha (MIP1A), MIP3A and RANTES are among the 
cellular response factors secreted upon cathelicidin presence. 51-53. 
4.5.Chemokines in the pathogenesis of AD 
Keratinocytes are mainly responsible for upregulating IL1α, IL1β, TNFα and Granulocyte 
colony stimulating factor (GM-CSF) following mechanical and inflammatory disruption of 
skin barrier in AD 54, 55. Proinflammatory cytokines mediate the production of chemokines and 
induce infiltration and survival of leukocytes in the skin. 
Development of pruritus on the other hand, is mainly mediated by IL31. Stimulation of the skin 
by staphylococcal superantigens results in expression of IL31 from Th2 cells in AD patients 
56. Furthermore, IL31 overexpressing mice display a dermatitis-like skin phenotype and severe 
pruritus 57. IL31 signals through the heterodimeric IL31RA and OSMR receptor pairing, which 
is expressed on skin resident monocytes, dendritic cells and keratinocytes. IL31 signalling 
activates expression of skin homing factors such as CC chemokine ligand 1 (CCL1), CCL17 
and CCL22, which in turn lead to increased numbers of CLA+ T cells in the skin. Th2 cells in 
the skin express IL31 in response to danger signals and this cycle of inflammation makes IL31 
one of the key cytokines behind the formation of atopic lesions and the pathogenesis of AD. 
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Previous studies have demonstrated that a plethora of chemokines, among them CCL1, CCL2, 
CCL3, CCL4, CCL5, CCL11, CCL13, CCL17, CCL18, CCL20, CCL22, CCL26 and CCL27 
are upregulated in AD skin 58-60 (Figure 1). From this knowledge, it can be deduced that 
inflammatory infiltrate constitutes an important aspect of the lesional AD skin. Skin homing 
cells into AD skin consist mainly of memory T cells, as well as eosinophils, mast cells and 
dendritic cells 61. 
Most studied among the chemokines, CCL27 is a skin specific chemokine expressed only by 
epidermal keratinocytes. CCL27 expression is increased by IL1β and TNFα stimulation. 
CCL27 and its receptor CCR10 regulate T cell infiltration into the skin. CCL27 knock-out or 
neutralizing mouse models have greatly decreased skin inflammation 58.  
CCL18 expression is not specific to skin. However, CCL18 was reported to be one of the 
chemokines that show the greatest upregulation in lesional AD skin, as well as having a strong 
correlation with AD severity compared to healthy skin 60. CCL18 binds specifically to CLA+ 
memory T cells and may regulate their recruitment into the skin 62.  
CCL1 is also reported to be significantly upregulated in AD skin and blood. CCL1 was first 
described as an anti-apoptotic factor for lymphocytes, and its expression in skin is induced by 
microbial toxins, as well as foreign materials. It is thought that CCL1 stimulation of immune 
cells that infiltrate skin contributes to their survival in tissue and support the inflammatory 
environment in lesional sites 63. 
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Figure 1. Significantly regulated Chemokine genes in lesional AD skin in comparison to non-
lesional AD skin. Majority of the chemokines are observed to be upregulated in lesional AD 
skin. (fdr<0.01). (Unpublished data Altunbulakli et al.) 
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4.6. Role of T Cells in AD 
Cellular infiltrate into the AD skin tissue is thought to be one of the major factors leading to 
lesion formation. Most of the cells infiltrating AD skin belong to a memory T cell subset 
bearing cutaneous-lymphocyte-associated antigen (CLA). CLA expression selectively guides 
T cells to cutaneous locations and is expressed on Th1 cells. CLA is upregulated also on Th2 
cells upon stimulation with IL12 and various bacterial superantigens.  
A large proportion of allergen specific T cells encountered in AD skin are Th2 cells producing 
IL4, IL5 and IL13. These cytokines are influential in the inhibition of barrier molecules. 
However, IFNγ is known to be a factor that is increased in expression in older and chronic skin 
lesions, while IL4, IL5 and IL13 also remain at high levels in chronic AD lesions. IFNG and 
accompanying IL1α, IL1β, IL12, IL18 is thought to inhibit growth factors and healing factor 
in AD skin, contributing to the chronicity of lesions. Overall, we see a paradigm shift in AD 
lesions, microinflammation exists in the form of Th2 type cytokines in non-lesional skin and 
early lesions, but Th1 cytokines dominate late and chronic lesions while Th2 cytokine 
expression persists. 
Furthermore, IL25 is proposed as a target molecule to combat Th2 mediated inflammation in 
AD. IL25 belongs to IL17 family of cytokines, and mainly acts on macrophages, basophils and 
eosinophils to initiate a Th2 type immune response 64, 65. IL31 is also produced by Th2 cells 
and is thought to be the main factor behind pruritus and scratching damage in AD. IL33 
upregulation is known to play role in the mediation of eosinophilic inflammation in AD lesions 
66, 67.  Finally, IL36 family cytokines IL36A, IL36G and IL36RN are heavily upregulated in 
AD lesional skin, but their exact function in the inflammation of skin is currently unknown 
(Figure 2). 
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Treg cells are thought to be influential in suppression of IgE production and instead induce 
IgG4 production by B cells in AD by IL10 and Transforming growth factor beta (TGFβ). IL10 
and TGFβ are also reported to suppress degranulation, histamine and pro-inflammatory 
cytokine production from effector cells such as Mast cells, basophils and eosinophils. However, 
the full extent of effect of Treg cells on AD lesions is currently unknown. A Treg dysfunction 
on the anti-inflammatory cytokine production capacity and suppression capability have been 
proposed for AD. 
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Figure 2. Significantly regulated Interleukin genes in lesional AD skin in comparison to non-
lesional AD skin. (fdr<0.01). 
 
 
 
 
23 
 
4.7. Role of Mast cells, basophils and eosinophils in AD 
Mast cells and basophils are important mediators of hypersensitivity reactions. The numbers 
of mast cells and basophils increase in AD lesional sites, and these cells are considered as 
contributors to pruritic reactions. Mast cells and basophils are capable of producing IL4, IL5, 
IL6, IL8, IL10, IL13, as well as TNFα, GM-CSF and TGFB. Histamine and various other 
mediators of inflammation such as Tryptase, Chymase and Cathepsins are released upon Mast 
cell and basophil degranulation. 
Mast cells and basophils express the high affinity IgE receptor FCeR1, and they undergo 
degranulation upon dimerization of FCeR1 an IgE molecule. This activates the Syk 
phosphorylation pathway and leads to relocalization of cytoskeletal elements responsible for 
anchoring histamine containing intracellular vesicles.  
Eosinophils infiltrate inflammatory cutaneous sites similar to lymphocytes, Mast cells and 
basophils. These cells are capable of producing a wide variety of pro-inflammatory foctors 
including IL1α, TGFα and TGFβ1, GM-CSF, IL3, IL4, IL5, IL6, IL8 and IL12. Eosinophils 
also possess granulocytic molecules that can release cytolytic enzymes such as EPO, MBP, 
ECP and EDN. Eosinophil involvement is thought to be influential is lesional skin pathogenesis 
by causing vasoactivity, cytotoxicity and pruritus.  
Activity of Mast cells, basophils and eosinophils are closely tied to IgE-mediated 
inflammation, and 70%-80% of extrinsic AD patients display increased IgE levels in 
circulation. These include allergen-specific IgE, but Staphylococcal entrerotoxin-specific IgE 
is an important finding that may play a role in the pathogenesis of AD.  
4.8.S. aureus and AD 
Infection has been proposed as one of the triggers of AD. In line with this, it is generally known 
that S. aureus is one of the pathogens found in AD lesions 68. S. aureus is encountered in over 
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90% of AD patients, its abundance is correlated with AD severity and AD lesions contain a 
much higher frequency of S. aureus compared to healthy skin 69, 70. 
S. aureus colonisation in AD is thought to be linked to skin inflammation, defects in skin barrier 
and innate immunity. Th2 cytokines IL4 and IL13 are known to increase the frequency of S. 
aureus colonization in skin and enhance S. aureus binding 71 . Furthermore, IL4 and IL13 are 
also capable of suppressing local skin innate immunity, mainly in the form of decreasing 
expression of anti-microbial peptides. Anti-microbial peptides Human beta defensin-2 (HBD-
2) and HBD-3 are capable of directly killing S. aureus, but their expression is decreased in AD 
patients 72, 73. 
The best studied virulence factors produced by S. aureus are the staphylococcal superantigens. 
These include staphylococcal enterotoxin A (SEA), SEB, SEC, SED and toxic shock syndrome 
toxins such as TSST1. Superantigens secreted from S. aureus on AD skin such as 
Staphylococcal enterotoxin B are thought to contribute to lesion development. CD8+ T cells 
resident to the skin proliferate upon stimulation with staphylococcal superantigens, and Th2 
cells isolated from human skin produce high amounts of IL5 and IL13 upon superantigen 
stimulating. Epidermal macrophages and Langerhans cells also produce pro-inflammatory 
cytokines IL1, TNF and IL12 upon superantigen stimulation.  
SEB and various other enterotoxin specific IgE and IgG were also measured in AD patients 
and is thought to contribute to severity of AD exacerbations by increasing mast cell and 
basophil degranulation and histamine release.  
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4.9.Pathogenic fungi and AD 
Changes in fungal microbiome of skin have been previously described in both lesional and 
non-lesional skin of AD patients. Various Malassezia species, as well as yeast species such as 
Candida albicans increase in frequency in the lesional skin, as well as non-lesional skin of AD 
patients compared to healthy skin 74.  
Decrease in the expression of cathelicidin molecules, such as LL37, as well as decrease in anti-
microbial peptides Beta defensins are thought to facilitate Malassezia colonization of lesional 
AD skin 75, 76. Malassezia-specific IgG and IgE are measured in AD patients, which is thought 
to contribute to increased IL1, IL2, IL4 and IFNγ response in lesional AD skin 77-79.Extensive 
sequencing of the fungal microbiota would be needed to document the full contribution of 
pathogenic fungal species to development of lesions in AD patients. 
4.10. Viral infections and AD 
The contribution of viral infection to allergic skin diseases, in particular AD is an under-
researched area. It is thought that the inherent barrier disruption on AD patients, as well as the 
shift in the adaptive immune mechanisms by excessive production of Th2 cytokines as opposed 
to downregulation of virus protective Th1 cytokines is thought to facilitate virus infections at 
lesion sites 61. 
Infections of Molluscipox double stranded DNA virus, Vaccinia virus and Herpes Simplex 
virus are known to accompany AD 80-82.  
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Abstract 
Background: Host-microbe interactions play a critical role in the pathogenesis of atopic 
dermatitis (AD). However, it is unclear if changes in the microbiota affect the host immune 
status and skin barrier function, or vice versa, and how they together influence AD.  
Objective: This study aimed to find a link between microbiome and transcriptome of lesional 
and neighboring non-lesional skin of AD patients.  
Methods: Microbiome 16S sequencing in skin swabs and RNA-seq transcriptome from skin 
biopsies at same location of AD patients (N=13, lesional and non-lesional pairs) and healthy 
controls (N=7) were sequenced. Both data-sets were then correlated utilizing a bootstrap 
approach for correction of multiple testing.  
Results: Global beta diversity of skin microbiome separates both AD skin from healthy skin, 
whereas skin transcriptome differentiates lesional from non-lesional skin. The reduction in 
microbiome diversity observed in AD lesional skin is a result of a significantly increased 
frequency of S. aureus, rather than a reduction in richness. Frequency of S. aureus shows a 
negative correlation with other Staphylococcus species in AD subjects. Downregulaton of the 
majority of tight junction genes; together with expression signature changes were observed in 
skin barrier gene families in lesional AD samples. Negative correlations between S. aureus 
with tight junction genes claudin 4 and 5 and zona occludens 1 and 2 were observed in lesional 
AD skin. Positive correlations were observed between S. epidermidis, S. hominis and S. 
haemolyticus with the same genes.  
Conclusions: Simultaneous analysis of skin transcriptome and microbiome revealed 4 skin 
barrier genes that are differently correlated to a Staphylococci dominated dysbiosis in skin 
microbiome, potentially pointing to a mechanistic interaction between specific tight junction 
genes and specific Staphylococcus species as candidates for intervention. 
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Key messages: 
• Staphylococci dominated dysbiosis, rather than reduced richness, is the reason for a 
reduced microbiome alpha diversity in atopic dermatitis.  
• S. aureus abundance is negatively correlated to all other staphylococci, possibly indicating 
an out-competition process. 
• Gene expression of specific tight junction genes (CLDN4, CLDN5, TJP1 and TJP2) in 
lesional skin was negatively correlated with S. aureus abundance and positively correlated 
with S. epidermidis, S. hominis and S. haemolyticus, suggesting these genes and 
Staphylococcus species as targets for therapy. 
Capsule summary 
Skin microbiome and transcriptomics correlation in atopic dermatitis patients reveals 4 tight 
junction genes (CLDN4, CLDN5, TJP1 and TJP2) as being correlated with staphylococci 
abundance. This provides a rationale for intervention by influencing the microbiota. 
Key words: Atopic dermatitis, eczema, skin barrier, transcriptome, microbiome, lesional skin, 
non-lesional skin, Staphylococcus, tight junctions, multiple testing correction. 
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Introduction 
Atopic Dermatitis (AD) is an inflammatory skin disease with dramatically increasing 
prevalence in industrialized countries over the last decades. AD affects 25 % of children and 
up to 10 % of adults1 and many of those develop allergic rhinitis or asthma over the years.2 
Alongside genetic risk factors, like mutation in the barrier protein filaggrin, environmental 
factors, such as skin microbiota, are increasingly acknowledged to be a main risk factor for 
AD.3-7 A reduction in the microbiome diversity, as well as a higher abundance of 
Staphylococcus aureus, is observed in lesional AD skin correlating with lesion severity.8-10 
Furthermore, different S. aureus strains, with varying ability to produce entero- and exo-toxins, 
are associated with differences in disease severity.11-13 In the Adam17ΔSox9 mouse model, which 
lacks the key matrix metalloproteinase ADAM17 that is important for bacteria restriction in 
epithelial tissues, it was shown that S. aureus drives eczema formation and antibiotic treatment 
reverses this process.14 However, it is still unclear whether the altered microbiota is a cause or 
consequence of AD in humans.7, 15 
Epidermal barrier dysfunction is an essential factor related to the pathogenesis of AD. 
The skin acts as a physical barrier against invading pathogens by a layer of differentiated 
keratinocytes in stratum corneum (SC) and a system of junction complexes in living epidermal 
cells of the stratum granulosum.16 These junction complexes include: tight junctions (TJ)17, 
which form a branching network of proteins that seal the space between adjacent cells. In 
addition, gap junctions (GJ)18, which are formed of connexin channel complexes, regulate 
small molecule passage between cells and thus cell to cell communication. Finally, the 
desmosomes (DS) and adherens junctions (AJ)19, which act as anchoring complexes binding 
cell to cell and cell to extracellular matrix.  Previous studies of AD skin have shown the 
disruption of skin barrier (e.g., filaggrin, claudin-1, claudin-4 and claudin-23) both in terms of 
gene expression and protein localization.20-23 
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It is well-known that the human skin and skin immune system are able to influence the 
skin microbiota and vice versa.24 For example, the loss of skin barrier integrity may easily 
allow invasion of bacteria.25 In addition, keratinocytes are producers of antimicrobial peptides 
(AMP) like human β-defensins, cathelicidins, RNAses and pattern recognition receptors like 
toll-like receptors.26-28 Conversely, S. aureus was shown in-vitro and in porcine model to 
decrease density and expression of tight junction proteins such as claudin-1, zona occludens 
ZO-1 (with associated gene TJP1), ZO-2 (TJP2), occludin and adherens junction protein E- 
cadherin.29, 30 However, there is no information on the correlation between skin barrier function 
and microbiota in-vivo in AD patients. In this study, we pursued a “joint-omics” approach 
aiming to uncover possible correlations between the skin microbiome and the skin 
transcriptome in the context of AD (see workflow in supplementary Fig E1). This approach 
has been taken in the gut and other tissues but to our knowledge not in human skin or in relation 
to atopic dermatitis.31, 32 We had started by analysing in parallel the global microbiome and 
global transcriptome. Due to the heavy multiple testing involved in identifying significant 
correlations between such two “big-data” sets, it was necessary to find a way to reduce the 
dimensions of the system. Thus, for reasons further explained below, we focused the analysis 
on the abundance of Staphylococcus species and on skin barrier gene expression in lesional 
and non-lesional skin from AD patients.  
Materials and Methods 
Patient recruitment and sampling 
The Ethical Committee of Technical University of Munich approved all human subject 
recruitment and sample collection. Exclusion criteria included self-reported antibiotic 
treatment (oral or systemic) 6 months before enrollment. Subjects were instructed to avoid hand 
sanitizers and antimicrobial soaps and skincare products for 1 week and not to shower 24 hours 
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before the sample collection appointment. A total of 13 AD patients, with a lesion in the upper 
arm (mean SCORAD 57.3, range 32-99.5), and 7 healthy controls were included in the study 
(supplementary Fig E1 and see characteristics in Table E1). Both swabs for microbiome 
analysis and 4 mm biopsies for transcriptomics analysis were taken from the lesion upper arm 
area and from an adjacent non-lesion area.  
 
Table E1: Patients‘ characteristics and sample availability 
Patient Gender 
Age 
[years] 
BMI SCORAD 
Total 
IgE 
Microbiome Transcriptome 
LS NL LS NL 
AD02 m 23 25.2 40 224 0 0 1 1 
AD03 m 34 23.8 50.82 9983 1 1 1 1 
AD04 f 49 20.4 70 435 1 1 0 1 
AD05 m 67 19.8 79 66.66 1 1 1 1 
AD06 f 46 45.7 66 17.4 1 1 1 1 
AD07 m 46 15.8 53 27287 1 1 1 1 
AD08 m 61 21.6 32 9.7 1 0 1 1 
AD09 f 62 23.2 34.3 7.38 0 1 1 1 
AD10 m 18 22.7 99.5 460 0 1 1 1 
AD11 m 28 24.1 49 6398 1 1 0 0 
AD12 m 86 24.8 51 ND 0 0 1 1 
AD13 f 52 27.4 80 184 0 0 1 0 
AD14 f 21 24.8 40 25.5 0 0 1 1 
Total   7 8 11 11 
Paired LS and NL 6 10 
Paired Microbiome and Transcriptome 5  7 5 7 
Healthy Gender 
Age 
[years] 
BMI SCORAD 
Total 
IgE 
Microbiome Transcriptome 
HE HE 
HL01 f 50 31 0 ND 0 1 
HL02 f 26 22 0 ND 0 1 
HL03 f 48 34 0 ND 1 1 
HL04 f 50 23.1 0 17.9 1 0 
HL05 f 26 25.2 0 2.79 1 1 
HL06 f 36 20.8 0 46.8 1 1 
HL07 m 31 30.0 0 233 1 1 
Total 5 6 
 Paired Microbiome and Transcriptome 4 4 
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Supp. Figure E1: Schematics of study design and methodology. Swabs and biopsies from 
the same skin area collected from AD patients (N=13) and healthy controls (N=7) were 
processed, sequenced and analysed in parallel for global microbiome and transcriptomics. In 
order to reduce multiple testing, we then focused on Staphylococcus species and on skin barrier 
genes for more detailed analysis and correlation of the both. 
 
 
 
 
 
 
Skin
swabs
Microbial  
DNA   
Isolation & 
Amplification
16s DNA 
Sequencing
(V1-V2-V3)
Microbiome 
Global  
Diversity 
Analysis
Transcriptome 
N=20 Samples 
(LS:7  NL:8  HE:5) 
Shuffling Bootstrap       
for multiple testing 
correction (MTC)  
of correlations 
Identification of 
MTC correlations 
between skin 
barrier gene 
expression and 
frequency of 
Staphylococcus 
spp. 
Analysis of 
Staphylococcus 
species 
Skin 
punch 
 biopsies 
Human      
RNA   
Isolation & 
Amplification 
NGS 
RNAseq 
sequencin
g 
Transcriptome 
Global   
Diversity 
Analysis 
Sample 
collection 
Atopic 
Dermatitis 
(AD) 
patients 
(N=13).  
Sample 
taken from 
Lesion (LS) 
and Non-
Lesion (NL). 
Healthy 
(HE) 
controls 
(N=7).  
Differential 
Expression 
analysis of      
Skin Barrier 
Genes 
N=28 Samples 
(LS:11  NL:11 HE:6) 
Microbiome 
N=16 Combined   
                 Samples 
(LS:5  NL:7  HE:4) 
40 
 
Collection and processing of skin swabs and microbiome sequencing  
Cutaneous swabs (Sigma-Swab®, Medical wire, Corsham, Wiltshire, England) were collected 
as described previously32, 33, stored at -80°C, and processed to extract DNA as described in the 
Supplementary Material. DNA samples were amplified using the variable regions 1 to 3 of the 
16S RNA gene to be able to separate different Staphylococcus species.34 All samples were 
equimolarly pooled into one library using 2 multiplexing barcodes per samples. Bidirectional 
sequencing, using a MiSeq® Nano v3 (Illumina Inc.), resulted in 2 x 300 bp paired-end (PE) 
reads (see details in Supplementary Material). At each sampling, swab controls without any 
skin contact were processed parallel to experimental samples. No significant background 
contamination was observed from either reagents and/or collection procedures. 
Primary microbiome data analysis, including signal processing, de-multiplexing and 
trimming of adapter sequences was performed using the MiSeq® Reporter 2.5.0.5 software. 
Thereafter, the bioinformatics software tool CLC Genomics Workbench 8.5.1 with the 
Microbial Genomics Module (Qiagen) was used for quality trimming, merging and clustering 
(see details in Supplementary Material). Operational taxonomic units (OTU) were clustered at 
a 97% identity threshold, according to the taxonomy of the SILVA 16S rRNA sequence 
database (www.arb-silva.de). To identify specific species – especially Staphylococci – the 
OTUs of interest were re-identified using EzBioCloud for similarity-based searches against 
quality-controlled databases of 16S rRNA sequences.35 
Collection and processing of skin biopsies and transcriptome sequencing 
Punch biopsies (4 mm) were immediately transferred in RNAlater®-Solution (Life 
Technologies, Carlsbad, CA, USA), at 4°C overnight and thereafter stored at −80°C. Total 
RNA was prepared from whole skin tissue using the RNeasy mini Kit (QIAGEN, Hilden, 
Germany). The quantity and quality of the isolated RNA was determined with a Qubit® (1.0) 
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Fluorometer (Life Technologies, California, USA) and a Bioanalyzer 2100 (Agilent, 
Waldbronn, Germany) and samples with RNA integrity number >7.0 were chosen for 
sequencing. Library preparation for RNA-seq was performed using the TruSeq Stranded 
mRNA Sample Prep Kit (Illumina, Inc, California, USA) and Illumina HiSeq 2500 single end 
126 or 101 bp (Illumina, Inc, California, USA) was used for sequencing (see details in 
Supplementary Material). 
Bioinformatics analysis of microbiome data 
A number of microbiome samples were excluded (see details in supplementary Table E1 and 
Fig E1) from analysis due to technical problems or low sequencing depth (<1000 reads), 
resulting in N=20 samples in the analysis, which show no significant difference in sequencing 
depth between the 3 skin groups and no dependence of the number of OTUs observed as 
function on sequencing depth (supplementary Fig E3). After a normalized OTU table was 
obtained the alpha-diversity of the global microbiome was assessed for each sample using a 
number of methods: Richness, Inverse Simpson Index and Normalized Shannon Entropy. In 
addition, we analyzed the frequencies of the most abundant families and species and of specific 
species of interest (e.g. staphylococci). For each OTU, species and family, we also 
characterized the span (%-detectable-samples) over all the samples and, more importantly, over 
each sub-group of samples (i.e. lesion, non-lesion and healthy). Beta-diversity analysis of the 
global microbiome was performed using MDS and hierarchical trees to look for differences 
between sub-groups of patients using the RHEA R-script package36. The more detailed analysis 
of Staphylococcaceae, and their correlation with transcriptome, was performed on 22 (out of 
54) Staphylococcus spp. annotated OTUs that had a minimum total abundance of 30 reads and 
minimum span of 25% over all samples.   
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Supp. Figure E3: Microbiome richness normalized by sequencing depth. The global 
microbiome richness (number of OTUs) per sample is not dependent on the depth of 16S 
sequencing, thus indicating that we had reached a sufficient sequencing depth in the samples 
included in the analysis (A). The normalized richness (number of OTUs divided by number of 
total reads) is not different between the 3 skin groups (B).  
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Bioinformatics analysis of transcriptome data 
A number of transcriptome samples were excluded (see supplementary Table E1 and Fig E1) 
from analysis due to technical problems or low RNA yield, resulting in N=28 samples in the 
analysis, which show no quality control problems. Gene and isoform level abundances were 
quantified as RPKM values. Clustering analyses were performed using the “ward.D2” 
clustering algorithm implemented in the “hclust” function of R statistics package. Heatmap 
plots were performed with the function “heatmap.2” implemented in the gplots R package. 
Differential expression analysis between groups was performed using edger R bioconductor 
package.37 More detailed analysis and correlations tested with the microbiome for the 135 skin 
barrier genes that were differentially expressed between non-lesional versus and lesional skin 
or between healthy versus non-lesional skin with FDR lower than 0.01. 
Analysis of correlations between microbiome and transcriptome 
Because of the extensive multiple testing involved in correlating the microbiome data with the 
transcriptome data, we had taken a bootstrap approach to correct for false discovery of 
correlations. In short, we had generated 100 bootstrap sets, in which the microbiome data was 
kept the same, but the transcriptome data was randomly shuffled between the samples such that 
>80% samples were different from their original data. Subsequently, correlation tests were 
performed on all the shuffled bootstrap sets to generate the distribution of R scores and p-
values obtained in the randomly shuffled data due to multiple testing. Finally, correlations from 
the real data were considered as multiple testing corrected (MTC) significant only if their R-
scores (p-values) were higher (lower) than those obtained from the bootstrap random sets. This 
process was performed separately for each combination of data sets being correlated (e.g. 
correlating Staphylococcus species with tight junction genes, with gap junction genes etc.) in 
order to keep the original structure of the data. 
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Statistical analysis 
The non-parametric Mann-Whitney (or Kruskal-Wallis) test was used to verify the statistical 
significance of difference in continuous variables between 2 (or 3) sub-group of samples. The 
statistical significance of difference in proportions of discrete data between sub-groups of 
samples was tested using the Fisher Exact test. Correlations between continuous variables were 
assessed using the non-parametric Spearman test. Significant p-values were considered at the 
two-tailed level of p<0.05 unless correction for multiple testing was needed, in which case the 
FDR results were used, or a bootstrap method was used as described above. 
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Results 
Beta-diversity analysis of the microbiome and transcriptome. 
Global beta-diversity analysis of the microbiome samples using multi-dimensional scaling 
analysis (MDS) shows that healthy samples are significantly separated from the lesional and 
non-lesional AD samples (Fig 1A). However, we do not observe a significant separation 
between lesional and non-lesional skin samples using beta-diversity analysis of the 
microbiome. Hierarchical clustering and 3D MDS confirm this observation (Fig 1C and Supp. 
Fig E2A).  
On the other hand, beta-diversity analysis of the transcriptome in same patients, using 
principal component analysis (PCA) of the first two components (Fig 1B), or hierarchical 
clustering of all genes (Fig E3B), show that lesional AD skin clusters separately from the other 
samples, while non-lesional AD skin and healthy skin are not significantly separated. 
Nevertheless, PCA analysis of the transcriptome using the first three principal components (Fig 
1D), or hierarchical clustering of only the top 100 variable genes (Fig E2C), also separates the 
non-lesional AD samples from the healthy samples. 
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Figure 1: Beta-diversity of global skin microbiome and transcriptome. NMDS 
clustering of skin microbiome separates healthy (HE) skin samples from AD (lesion, LS, and 
non-lesion, NL) samples (A), while 2-components PCA clustering of skin transcriptome (B) 
differentiates between lesion (LS) samples versus non-lesion (NL) and healthy (HE) skin 
samples, while the latter are not well differentiated. The scale for the NMDS distance (d) is 
given in A and the contribution of each principal component (PC) is given in B. 3D NMDS 
clustering of skin microbiome shows similar effect on separating HE samples from AD (C) 
while 3-components of PCA clustering on skin transcriptome can differentiate HE, NL and LS 
skin (D). 
 
 
47 
 
 
 
 
 
 
 
 
Supp. Figure E2: Hierarchical clustering of microbiome and transcriptomics. Beta-
diversity, as assessed by hierarchical clustering, of the global skin microbiome (A) separates 
AD lesional (LS) and non-lesional (NL) samples from healthy (HE) skin, clustering of the with 
one exception, while for transcriptomics the clustering of all genes (B) separates lesional 
samples from the others, but clustering of only the top 100 genes (C) separates all 3 skin groups. 
 
 
 
 
 
 
 
 
A B C 
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Decreased microbiome alpha-diversity in AD samples is due to increased frequency of 
Staphylococcus aureus and not to a loss in richness.  
Alpha-diversity of the global microbiome (inverse Simpson Index) is significantly reduced in 
AD lesional (mean SI=3.2, p=0.003) and non-lesional (SI=6.3, p=0.003) compared to healthy 
(SI=17.6) skin (Fig 2A). In addition, the diversity is significantly (p=0.028) lower in lesions 
than in non-lesions. Same results were observed with the Shannon entropy diversity index. 
However, this reduction in diversity is not due to a decreased richness (Fig 2B) or normalized 
richness (supplementary Fig E4), which are not different between the 3 skin groups. Rather, 
the significantly increased frequency of the most-abundant OTU in lesions versus non-lesions 
versus healthy (Fig 2C) is the main cause for the differences in the diversity. In fact, the most 
abundant species in all AD samples except one1 is S. aureus, while in the healthy skin samples 
the most abundant species is idiosyncratic but not S. aureus. Indeed, when S. aureus is removed 
from the analysis, the diversity becomes significantly higher (3.1-fold, p=0.018) in the AD 
lesional samples, and 1.9-fold in non-lesional samples but stays the same in healthy samples; 
resulting in no difference between lesions and not affected skin of AD and both closer to the 
healthy skin (Fig 2A). Moreover, Staphylococcaceae is the only family whose frequency is 
significantly (p=0.003) increased in AD (mean 63%) compared to healthy (11%), and also 
significantly (p=0.028) higher in lesional (73%) compared to non-lesional (54%) skin (Fig 2D). 
 
 
 
                                                          
1   In 1 non-lesional sample S. aureus is not the most abundant species but it is the second 
most abundant. 
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Figure 2: Alpha-diversity analysis of the global microbiome. The Inverse Simpson index of 
diversity, when using all OTUs per sample, is significantly reduced in AD skin versus healthy 
(HE) and furthermore significantly reduced in lesional (LS) versus non-lesional (NL) skin (A, 
left). However, microbiome richness (total number of OTUs) is not different between the 3 
groups (B), while the frequency of the most abundant OTU per sample, which is S. aureus in 
14/15 AD samples, is significantly increased in AD skin versus healthy (HE) and furthermore 
significantly increased in lesional (LS) versus non-lesional (NL) skin (C). Indeed when S. 
aureus OTUs are removed from the Simpson index analysis the diversity of the lesion samples 
significantly (p=0.018) increases and the difference between the groups is reduced (A, right). 
Staphylococcaceae is the only family that is significantly (p=0.003) more abundant in AD 
samples (D), revealing the Staphylococcus dominated dysbiosis. 
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Negative correlation between the frequencies of Staphylococcus aureus and the other 
Staphylococcus spp. 
Considering the above results and the fact that it is needed to reduce the extent of multiple 
testing for the correlation analysis, we decided to focus on the Staphylococci family, for which 
we identified 7 different species (Fig 3A and Table 1), and identified an interesting dysbiosis. 
Staphylococcus aureus, spanning all the AD samples, has the highest frequency in lesional skin 
(mean 65.2%), which is significantly (p=0.028) higher compared to non-lesional skin (39.8%). 
However, S. aureus is found only in 40% of the healthy samples with a significantly (p<0.004) 
lower frequency (0.5%). In contrast, S. epidermidis has significantly (p=0.046) higher 
frequency in non-lesional (7.6%) as compared to lesional (4.7%) skin, and a lower frequency 
in healthy samples (2.8%). As a third point, S. hominis frequency is similar between non-
lesional (3.4%) and healthy (3.8%), which are both significantly (p=0.018) higher than lesional 
skin (0.5%). S. caprae shows a similar pattern like S. hominis, as can be seen by the differential 
abundance patterns in the heatmap (Fig 3B). S. haemolyticus has the same range of abundance 
over the 3 skin groups with a somewhat higher span in healthy (80%) versus AD (60%) 
samples. A significant difference is found also for S. warneri, but its abundance is very low 
(Table 1). 
S. epidermidis and S. aureus are significantly (p<0.003) negatively correlated with each 
other in lesional (Rho= -0.96) skin and for all AD (Rho= -0.75) samples (Fig 3C). In general, 
in the AD samples S. aureus is significantly (p<0.05) negatively correlated to the 4 other most 
abundant Staphylococcus species, which show positive correlation with each other (Fig 3D).  
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Figure 3: Different frequencies of Staphylococcus species. The frequencies of 
Staphylococcus species show different abundance patterns in Healthy (HE), AD lesional (LS) 
and non-lesional (NL) skin, with only S. aureus most abundant in AD lesion (LS) samples, 
whereas S. epidermidis is most abundant in non-lesional (NL) skin and the other species are 
most abundant in healthy (HE) skin (A and B). S. aureus frequency is negatively correlated 
with that of S. epidermidis and all other staphylococci, which are positively correlated with 
each other, in lesional (LS) skin (C and D). Heatmap of fold change expression values (FCH) 
is scaled from blue to red in B and heatmap of correlation coefficients (R) is scaled from orange 
to green in D. 
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Table 1: Staphylococci frequencies per atopic dermatitis status 
 
a = Wilcoxon signed-rank test (paired) 
b = Mann-Whitney U test (independent) 
c = Percentage of patients in which the frequency of the respective Staphylococcus spp. is 
higher in the LS vs. NL site 
d = Mean of the ratio of Staphylococci abundance in LS vs NL paired samples  
* Significant for P < 0.05 
Freq. = frequency 
SEM = standard error of the mean 
AD = atopic dermatitis 
HE = healthy 
NL = AD Non-lesional 
LS = AD Lesional 
 
 ALL 
(N=20) 
Healthy 
(HE) 
(N=5) 
AD Non-
lesional 
(NL) 
(N=8; 6 
paired) 
AD Lesional 
(LS) 
(N=7; 6 
paired) 
LS vs Non-lesion AD vs Healthy 
Staphyloco
ccus spp. 
Mean 
±SEM 
Frequenc
y 
Spa
n 
Mean 
±SEM 
Frequenc
y 
Spa
n 
Mean 
±SEM 
Frequenc
y 
Spa
n 
Mean 
±SEM 
Frequenc
y 
Spa
n 
%patie
nts with 
freq.  LS 
> NL c 
Mean 
ratio 
(LS/NL) 
d 
P value a 
LS vs 
NL 
P value 
b 
LS vs 
HE 
P value 
b 
NL vs 
HE 
S. aureus 
38.9
% 
±6.7
% 
85% 
0.5
% 
±0.5
% 
40% 
39.8
% 
±7.0
% 
100
% 
65.2
% 
±7.5
% 
100
% 
100% 2.2 * 0.028 * 0.004 * 0.003 
S. 
epidermidi
s 
5.4
% 
±1.0
% 
100
% 
2.8
% 
±0.6
% 
100
% 
7.6
% 
±1.9
% 
100
% 
4.7
% 
±1.7
% 
100
% 
17% 0.6 * 0.046 0.93 0.1 
S. hominis 
2.5
% 
±0.8
% 
95% 
3.8
% 
±1.3
% 
100
% 
3.4
% 
±1.7
% 
88% 
0.5
% 
±0.2
% 
100
% 
50% 0.8 0.23 * 0.018 0.34 
S. 
haemolytic
us 
1.6
% 
±0.5
% 
65% 
1.8
% 
±0.8
% 
80% 
1.5
% 
±1.0
% 
63% 
1.5
% 
±1.0
% 
57% 17% 0.7 0.47 0.41 0.41 
S. caprae 
1.0
% 
±0.4
% 
80% 
1.3
% 
±0.8
% 
80% 
1.2
% 
±0.6
% 
75% 
0.6
% 
±0.5
% 
86% 33% 0.7 0.23 0.26 0.77 
S. warneri 
0.3
% 
±0.2
% 
55% 
1.0
% 
±0.7
% 
100
% 
0.1
% 
±0.1
% 
50% 
0.0
% 
- 29% 17% - 0.29 * 0.003 * 0.03 
S. xylosus 
0.1
% 
±0.1
% 
25% 
0.0
% 
- 20% 
0.2
% 
±0.1
% 
50% 
0.0
% 
- 0% - - 0.18 0.24 0.4 
53 
 
Analysis of the expression of skin barrier genes reveal widespread dysregulation in  
lesional and non-lesional AD skin. 
Because of the need to reduce the extent of multiple testing for the correlation analysis, we 
decided to focus on gene expression of cell adhesion molecules, which is the most significantly 
enriched differentially LS versus NL expressed gene group by GO and KEGG analysis (Table 
E2). Therefore, we analyzed the expression levels of the five skin barrier gene families: Tight 
junctions (TJ), stratum corneum (SC), gap junctions (GJ), desmosomes (DS) and adherens 
junctions (AJ). The majority (27/46, 58.6%) of the most abundant TJs are significantly 
(FDR<0.05) differentially expressed between lesional and non-lesional skin, of which 22 TJs 
(81%) are down-regulated in lesions, including claudin-1, -3, -4, -5 -7, -8, -9, -10, -11, -16, -
19, -23 and CLDND1 (Fig. 4A and 4B). Furthermore, claudin-1, F11r and occludin are 
significantly down-regulated in non-lesional and lesional skin compared to healthy skin. 
Conversely, expression of TJ adaptor molecules (such as MARVELD1, -D2, ZO-1 (TJP-1) and 
ZO-2 (TJP-2)), which mediate the connection of intercellular junctions to cytoskeletal 
components, is significantly up-regulated in lesional compared to non-lesional skin. 
Among the SC genes, filaggrin-1 is significantly down-regulated in AD skin compared 
to healthy, and filaggrin-2 is down-regulated in lesions in comparison to non-lesional and 
healthy skin (Fig. 4C and 4D). Part of the keratin genes was significantly up-regulated in 
lesional skin (e.g. keratin6A, 6B and 6C), whereas constitutively expressed keratins in healthy 
skin (e.g. keratin16) were overall down-regulated in AD skin. Similar expression signature 
changes were also observed in GJ and DS families (supplementary Fig E4A , E4B). Genes that 
are relatively low or not expressed in the steady-state skin transcriptome, such as GJB2, GJB6, 
DSC2 and DSG3 are significantly up-regulated in lesions compared to non-lesional and healthy 
skin. Whereas genes expressed at high levels in healthy skin, such as GJB4, GJC3 and DSG2 
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are significantly down-regulated in non-lesional AD skin, with further down-regulation in 
lesional skin. Lastly, the majority of significantly differentially expressed AJ genes (28/38, 
%73.6) are down-regulated in lesional skin (supplementary Fig E4C). Overall, the data show a 
significant downregulation of major barrier molecules in AD lesions together with the initiation 
of a healing process for certain keratins, GJ, desmosomes and adherens junctions. 
Table E2 – KEGG analysis of differentially LS/NL expressed skin transcriptome 
Term p-value Adjusted p-
value 
Overlap z-score Combined 
score 
Cell adhesion 
molecules – Homo 
sapiens – hsa04514 
7.85571x10-11 2.30172x10-8 89/142 
(62.6%) 
-1.725793996 30.35157747 
Cytokine-cytokine 
receptor interaction – 
Homo sapiens – 
hsa04060 
6.38294x10-10 9.351x10-8 144/265 
(54.3%) 
-1.853091474 29.99265139 
Pathways in cancer – 
Homo sapiens – 
hsa05200 
1.13005x10-9 1.10368x10-7 201/397 
(50.6%) 
-2.056392342 32.94226989 
Chemokine signaling 
pathway – Homo 
sapiens – hsa04062 
2.26831x10-9 1.66154x10-7 107/187 
(57.2%) 
-1.850351846 28.88464178 
Rheumatoid arthritis – 
Homo sapiens – 
hsa05323 
1.13405x10-7 6.64551x10-6 57/90 
(63.3%) 
-1.66018973 19.7920659 
AGE-RAGE signaling 
pathway in diabetic 
complication – Homo 
sapiens – hsa04933 
1.69444x10-7 7.03706x10-6 62.101 
(61.3%) 
-1.890556431 22.4301672 
Viral myocarditis – 
Homo sapiens – 
hsa05416 
1.63765x10-7 7.03706x10-6 41/59 
(69.5%) 
-1.725836015 20.47587141 
Inflammatory bowel 
disease – Homo 
sapiens – hsa05321 
1.92138x10-7 7.03706x10-6 44/65 
(67.7%) 
-1.702813886 20.20272949 
Apoptosis – Homo 
sapiens – hsa04210 
5.92328x10-7 1.92836x10-5 79/140 
(56.4%) 
-1.755632999 19.059604494 
Focal adhesion – Homo 
sapiens – hsa04510 
1.06875x10-6 3.13143x10-5 106/202 
(52.4%) 
-1.695697991 17.58682117 
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Figure 4: Differential expression of skin barrier gene families. The epidermal barrier 
genes are the most significant differentially expressed KEGG pathway group in AD related 
transcriptome (Table E2). Heatmap clustering of tight junction (A) and Stratum Corneum 
barrier (C) gene expression shows different patterns of differential expression. Most highly 
expressed tight junction (TJ) genes are significantly down-regulated in lesional (LS) skin, while 
some lower expressed TJ genes, and in particular TJ adaptor genes (e.g. TJP1), are up-regulated 
in lesion (B). Among the Stratum Corneum (SC) genes, the filaggrins are down-regulated in 
AD skin compared to healthy, and in particular in lesional skin, while the keratin genes show 
a mix of up- and down-regulation in AD and lesional skin (D). 
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Supp. Figure E4: Differential expression of skin barrier gene families. Heatmap clustering 
of gene expression of gap junctions, desmosomes and adherens junctions skin barrier genes 
show a mixed pattern of differential expression. 
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Correlation of microbiome and skin barrier transcriptome shows significance between 
Staphylococcus species and TJ gene expression in lesion. 
Finally, we correlated the frequency of the various Staphylococcus species with the expression 
level of the various skin barrier genes in each sample. This was done separately for each skin 
group or else the differences between the groups create false correlations that may mask the 
real correlations within each group. Furthermore, multiple testing correction was performed in 
order to avoid false discovery of correlations due to the large number of tests performed. Even 
after focusing on the Staphylococcus species (7) and skin barrier genes (135), still 945 
correlation tests were performed for each skin group. We had identified 63 potentially 
significant (p<0.05) correlations (see more detailed in supplementary Table E3); most of them 
between sporadic Staphylococcus species and sporadic genes. In order to verify these 
correlations, we had used a bootstrap approach, where the transcriptome results were randomly 
shuffled across samples to create 100 random sets of data in which <20% of the gene expression 
levels corresponded to the appropriate microbiome frequency of the same original sample. This 
approach had revealed that many seemingly significant correlations actually arise randomly 
due to multiple testing (Table E3). Only correlations with Rho=1 and p<0.017 had probability 
>99% to be real according to the Bootstrap results, and were defined as multiple testing 
corrected (MTC) correlations. Only 13 MTC correlations were found (out of the initial 63) and 
these only in lesional skin and only from the TJ family (Table E4). Indeed, most of the sporadic 
correlations were found to be non MTC, while 7 (54%) MTC correlations were found to be 
associated with 3 genes that had correlation with a number of Staphylococcus species.  
Of the 135 skin barrier genes tested, only 3 TJ genes were proven to have MTC 
correlations with more than one Staphylococcus species (Fig 5 and Table E4). Both CLDN4 
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and TJP1 gene expression levels in lesional samples were negatively MTC correlated with S. 
aureus frequency and positively MTC correlated with S. epidermidis and S. haemolyticus. 
However, the same correlations are not found in the non-lesional samples (Fig 5A-D). While 
the relation between lesional and non-lesional paired samples has the same direction as the 
cross-sectional correlation between lesional samples for CLDN4, it is nevertheless opposite to 
each other for TJP1 (Fig 5A-D). In addition, an MTC positive correlation was also found 
between CLDN5 and S. hominis in lesional samples (Fig 5G). Interestingly, all the 4 major 
Staphylococcus species were correlated (S. aureus negatively and S. epidermidis, S. hominis 
and S. haemolyticus positively) with 2 couples of related genes (CLDN4 and CLDN5; TJP1 
and TJP2), either by the above mentioned MTC correlations or by a non-MTC significant 
correlation (Rho>0.8 and p≤0.05) or by a trend (Fig 5E-H, Table E4). Lastly, 6 additional MTC 
correlations were identified between single Staphylococcus species and single TJ genes (see 
supplementary Table E4).   
Figure 5: Correlation between the frequency of Staphylococcus species and mRNA 
expression of tight junction genes.  A multiple-testing corrected (MTC) negative correlation 
is observed in lesional (LS, red) skin between S. aureus frequency and the expression level of 
tight junction genes CLDN4 (A) and TJP1 (B), while MTC positive correlation is observed 
between S. epidermidis and same genes (C and D). However, in non-lesional skin (blue) there 
is no correlation between Staphylococcus species and these TJ genes (A-D). The relation 
between lesional and non-lesional paired samples (dotted black lines) show the same direction 
as the correlation between LS samples for CLDN4 (A and C), but inverse direction for TJP1 
(B and D). In fact, in lesional skin, all the 4 major Staphylococcus species (S. aureus in red, S. 
epidermidis in light blue, S. hominis in green, S. haemolyticus in purple) show correlation with 
CLDN4 (E) and TJP1 (F), as well as with CLDN5 (G) and TJP2 (H). Solid lines depict MTC 
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correlations with rho=1 and p=0.017; Dashed lines depict correlations with rho>0.8 and 
p<0.05; Dash-dotted lines depict trends for correlations.  
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Table E3 – Number of (MTC) correlations in real data and in Bootstrap datasets 
 
 
 
 
 
 
 
 
Table E4 – List of MTC correlations and their association with other correlations with 
same skin barrier genes. 
 
 
 
 
 
 
 
 
 
Skin barrier family TJ GJ SC AJ Des ALL
50 21 19 30 15 135
350 147 133 210 105 945
Total 29  (8.3%) 12  (8.2%) 10  (7.6%) 11  (5.2%) 1  (1%) 63  (6.7%)
LS 22 7 1 6 0 36
NL 7 4 5 3 1 20
HE 0 1 4 2 0 7
32  (9.1%) 10  (6.8%) 10 (7.5%) 13  (6.2%) 6  (5.7%) 71  (7.5%)
1% 0% 0% 0% 0% 0.2%
Total 13 0 0 0 0 13
LS 13 0 0 0 0 13
NL 0 0 0 0 0 0
HE 0 0 0 0 0 0
Percent of bootstrap sets 
with correlation                 
with rho=1 & p=0.0167
Number MTC 
correlations with 
rho=1 & p=0.0167
Number (%)  of 
correlations with 
p<0.05
Number of Genes
Number of correlation tests 
with 7 Staph spp
Mean number of correl 
with p<0.05 in                    
100 boststrap sets
7  (54%)
Number MTC correl same 
gene with >=2 Staph spp
7  (54%) 0 0 0 0
Skin Group Gene Family Gene Staph Spp Direction Staph Spp Direction Rho p-value
LS TJ CLDN4 S. aureus NEG
LS TJ CLDN4 S. epidermidis POS
LS TJ CLDN4 S. haemoliticus POS
LS TJ CLDN4 S. hominis POS 0.8 0.13
LS TJ CLDN5 S. aureus NEG -0.8 0.13
LS TJ CLDN5 S. epidermidis POS 0.8 0.13
LS TJ CLDN5 S. haemoliticus POS 0.872 0.05
LS TJ CLDN5 S. hominis POS
LS TJ TJP1 S. aureus NEG
LS TJ TJP1 S. epidermidis POS
LS TJ TJP1 S. haemoliticus POS
LS TJ TJP1 S. hominis POS 0.8 0.13
LS TJ TJP2 S. aureus NEG -0.916 0.03
LS TJ TJP2 S. epidermidis POS 0.8 0.13
LS TJ TJP2 S. haemoliticus POS 0.872 0.05
LS TJ TJP2 S. hominis POS 0.872 0.05
LS TJ AMOTL2 S. caprae POS --
LS TJ CLDN2 S. hominis POS --
LS TJ CLDND2 S. haemoliticus NEG --
LS TJ JAM2 S. hominis POS --
LS TJ JAM3 S. caprae POS --
LS TJ MPDZ S. haemoliticus POS --
Also correlation withMTC Correlations (rho=1, p=0.0167)
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Discussion 
The main result of this study is the correlation between the staphylococci-dominated dysbiosis 
in skin microbiome with the dysregulation of skin barrier transcriptome in atopic dermatitis 
(AD) patients, in particular a correlation between all the 4 major Staphylococcus species (S. 
aureus negatively and S. epidermidis, S. hominis and S. haemolyticus positively) with only 4 
tight junction (TJ) genes (CLDN4, CLDN5, TJP1 and TJP2). Since correlations do not 
necessarily imply a causative relation, we cannot make definitive conclusions about the 
important question, if the microbiome dysbiosis is the cause for, or the result of, the skin barrier 
defect.38 If the increase in S. aureus is indeed the cause, e.g. by direct stimulation of cytokine 
secretion 39 or of endogenous proteolytic activity,40 then our results are highly important to 
focus on the specific tight-junction genes we had identified here as potential targets for therapy. 
In addition, the observed opposite correlations of S. aureus versus the 3 other major 
Staphylococcus species with skin-barrier transcriptome should be further studied in functional 
experiments to identify potential therapeutic approaches.  
On the other hand, a number of features of the correlations we observed might indicate 
that S. aureus increase is probably the result of, rather than the reason for, dysregulation in 
tight junctions. First, we observed a correlation between S. aureus and the TJ genes only in 
lesional skin, but not in non-lesional skin. If S. aureus would have been the cause, and 
considering that we find it in relatively high levels also in non-lesional skin, then we would 
expect a correlation also in non-lesional skin. In general, S. aureus frequencies are higher in 
lesion (mean 2.2-fold) as compared to non-lesional skin in same patients, but the cross-
sectional range of S. aureus levels in lesion largely overlaps that of non-lesion; thus there 
should be individual-patient thresholds for S. aureus to be the cause for lesion. Furthermore, 
we find a correlation between high S. aureus frequency and low CLDN4/5 RNA transcription 
level, but it is difficult to explain how S. aureus could cause a reduction in CLDN4/5 
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transcription. Indeed, there are some in-vitro studies claiming that S. aureus causes a reduction 
in claudin-430 and ZO-130, 41 or claudin-541 protein levels, but accompanied by an increase in 
CLDN4 and TJP1 gene expression30 rather than a decrease. The idea that S. aureus is not the 
cause would be consistent with in-vitro and murine models showing that skin barrier mutations 
affect S. aureus colonization and entry. 42,43 Also clinical studies show that S. aureus 
colonisation in neonates is not predictive of AD development later in life,44 in contrast to 
findings in older children with AD,45 where S. aureus is present but could be the result already. 
Alternatively, a mixed hypothesis could be that S. aureus is the cause for dysregulation 
of some TJ genes/proteins, but is the result of decrease in the gene expression of other TJ 
genes/proteins. Furthermore, instead of S. aureus being the cause or a result, a bi-directional 
feedback between S. aureus and skin barrier defect may exist, where only the combination of 
high S. aureus and low TJ expression gives rise to lesion formation. In that case, a correlation 
between the S. aureus levels and TJ genes would be indeed expected only in lesional skin but 
non-lesional skin.  
All 5 skin inter keratinocyte junctions and barrier families show significant expression 
changes in lesional and non-lesional AD skin in comparison to control biopsies, consistently 
with previous publications.46, 47 However, out of all skin barrier genes, we find a correlation 
with staphylococci abundance only in the TJ family, which makes sense considering that 
compared to other gene families studied here (GJ, AJ, SC, Des) TJs are on the top epidermis 
layer.48, 49 Furthermore, there are a few possible explanations why among all TJ genes, we see 
correlation of staphylococci abundance with only 4 genes, which are not the most highly 
expressed TJ genes (e.g. CLDN1 and OCLN). First, claudin-4 and ZO-1 (the protein product 
of TJP1) are expressed at the most surface of the top epidermis layer as compared to other TJ 
proteins30, 49, thus it is reasonable to expect that S. aureus has interaction particularly with these 
proteins. Second, it could actually be that the most highly expressed proteins are either not 
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drastically affected by S. aureus, if it is the cause, or that a reduction in their expression still 
leaves sufficient levels of that specific protein so that S. aureus cannot benefit from the 
reduction. In contrast, claudin-4/5 and ZO-1/2 that are medium-level expressed can either be 
stronger affected by S. aureus or a reduction in their level could bring protein levels to 
relatively low levels so that S. aureus may invade. Last possible explanation is that S. aureus 
has a specific relation with these 4 TJ proteins, as observed for claudin-4.50 
 The decline in microbiome alpha-diversity in AD patients as observed here has already 
been widely reported.31, 45 However, we show here that the change in diversity, either measured 
by inverse Simpson Index or by Shannon entropy is not due to a decline in the microbiome 
richness, which was found similar between healthy, lesion and non-lesional skin. Rather, we 
show that the frequency of the most abundant OTU, which is S. aureus in almost all AD 
samples has significantly increased in AD and is the major reason for the decreased diversity 
index. Indeed, when the diversity index is calculated without S. aureus then it is significantly 
increased in lesional skin and the difference to non-lesion skin disappears. In addition, S. 
epidermidis is higher in non-lesional skin and S. hominis is decreased from healthy to lesional 
skin, contributing to the dysbiosis. Thus, the observed microbiome dysbiosis in AD is majorly 
dominated by changes in staphylococci. 
 It was previously hypothesized that S. epidermidis and S. hominis could act as 
benevolent microbes to counteract the effect of S. aureus.44, 51-53 However, according to our 
results it seems that this is not true, since we see almost the same level of these species in 
lesional and non-lesional skin. The positive correlation observed between S. epidermidis, S. 
hominis and S. haemolyticus with the TJ genes is probably not due to a direct effect of these 
species on skin barrier, but rather because of the negative correlation of all these species with 
S. aureus, which in turn has a negative correlation with the TJ genes. The negative correlation 
between S. aureus and the other species is most probably due to a competition process. As a 
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second suggestion, all 3 species should be considered as beneficial, and that their negative 
correlation with S. aureus is due to their opposite effects on skin barrier. 
 Due to the large number of correlation tests performed in our study, multiple testing 
correction is needed to prevent false discovery of random correlations. However, it was not 
possible to use highly conservative methods for multiple-testing correction (e.g., Bonferroni) 
because of the relatively small number of samples. Therefore, we applied a shuffling (or 
permutation) Bootstrap procedure54, 55 to obtain null hypothesis data sets that have random 
relation between the microbiome and transcriptome, but nevertheless keep the data structure. 
This allowed us to identify thresholds for the correlation coefficient and the p-value that have 
less than 1% probability to be false. Indeed, almost all the multiple testing corrected (MTC) 
correlations were found between all 4 major Staphylococcus species and 2 gene pairs that were 
related to each other (CLDN4 and CLDN5, TJP1 and TJP2), in contrast to the large number of 
non-MTC correlations which linked sporadic staphylococci with sporadic genes. Nevertheless, 
a larger validation study is needed to confirm our results and this multiple-testing correction 
method for correlation of microbiome and transcriptomics. 
In summary, we identified 4 TJ genes whose expression is robustly correlated to the 
microbiome dysbiosis in atopic dermatitis patients. In addition, this study enabled us to better 
characterize the staphylococci-dominated dysbiosis and the relation between the various 
Staphylococcus species.  Further proteomics and functional studies are needed to elucidate the 
exact role these genes play in relation to changes in Staphylococcus species and in general to 
skin barrier dysfunction. Also, additional studies are needed to verify if specific metabolites, 
toxins or other products (e.g. AMPs 53) of these bacteria are interacting with the TJs or it is a 
direct interaction of the bacteria themselves. Furthermore, we had focused in this study on skin 
barrier genes but obviously it is important to correlate our results also to the immune response, 
which is our next step in analyzing our data. Even though we still cannot solve the AD chicken 
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and the egg question, our results do point out which particular bacteria and genes should be 
focused on. 
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Supplementary material 
Simultaneous skin microbiome and transcriptome analyses reveals a relation between 
staphylococci-dominated dysbiosis and barrier dysregulation in atopic dermatitis 
Methods 
Processing of skin swabs 
Cutaneous swabs (Sigma-Swab®, Medical wire, Corsham, Wiltshire, England) were collected 
as described previously33, and stored at -80°C immediately. Swabs were transferred to a bead-
beating tube with 500 µg of 0.1 mm zirconium glass beads (Carl Roth, Karlsruhe, Germany). 
For the following DNA extraction, the QIAamp UCP Pathogen Kit (QIAGEN, Hilden, 
Germany) was used. The original tube was rinsed with 650 µl lysis buffer, which was then 
transferred to the swab tube. Samples were incubated for 10 min at 56°C with continuous 
shaking and mechanically lysed using FastPrep (MP) twice for 20 s at 4.0 m/s with 1 min break 
between runs. The lysate was processed according to the QIAamp UCP Pathogen Mini Kit 
preparation protocol. 
16S rRNA sequencing 
All samples were amplified using the Primers 8F-YM (5’-AGAGTTTGATYMTGGCTCAG-
3’) and 517R (5’-ATTACCGCGGCTGCTGG-3’)56. The amplicons cover the variable regions 
1 to 3 of the 16S RNA gene. Each amplicon was purified separately applying the solid phase 
reversible immobilization (SPRI) paramagnetic bead-based technology (AMPure XP beads, 
Beckman Coulter) with a Bead: DNA ratio of 0.7:1 (v/v) following manufacturer´s instructions. 
Normalization of each amplification product to approximately 1ng/µl DNA was achieved using 
the Sequal-Prep Kit (Life Technologies).  
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A library was generated containing each of the amplicons from the 16S PCRs.  Additionally, 
two positive controls as well as two negative controls were also added to the pool. All samples 
except the controls were pooled equimolarly to form one library. The High Sensitivity DNA 
LabChip Kit (Agilent Technologies) was used on the 2100 Bioanalyzer system (Agilent 
Technologies) to analyze the quality of the purified amplicon library. Bidirectional sequencing, 
using a MiSeq® reagents kit 600-cycles Nano v3 (Illumina Inc.), results in reads of 300 bases 
in both directions, totaling 600 bases of sequence information in 2 x 300 bp paired-end (PE) 
reads. The Illumina software MiSeq® Reporter 2.5.0.5 on the MiSeq® system and the Illumina 
Sequence Analysis Viewer 1.9.1 were used for imaging and evaluation of the sequencing run 
performance. 
Primary analysis of microbiome data 
Primary microbiome data analysis, including signal processing, de-multiplexing and trimming 
of adapter sequences of the two read files was performed using the MiSeq® inherited MiSeq® 
Reporter 2.5.0.5 software. Furthermore, data was imported in the bioinformatics software tool 
CLC Genomics Workbench 8.5.1 (Qiagen) for quality trimming, merging of read 1 and 2 from 
each cluster and QC-Report generation. Clustering (OTU definition) was also performed using 
the CLC plugin Microbial Genomics Module. 
Demultiplexed raw data (read 1 and read 2 per sample) were imported into CLC Genomics 
Workbench as paired-end (forward-reverse) reads. A possible distance between 1 and 10’000 
bases was allowed. Failed reads were removed from the data set during this process. 
As a first step, read 1 and read 2 sequences from every sample were merged using the over-
lapping sequence information and taking the minimum overlap, potential mismatches, gaps and 
unaligned ends into account. The two reads were merged including a minimum of 20 bp 
overlaps without mismatch and maximum unaligned end mismatches of 2 bp. 
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Trimming of reads was performed according to primer sequences, base quality and read length, 
whereby a probability quality limit of 0.05 was applied. To guarantee similarity and a 
sufficiently high level of sequence information for phylogenetic classification, sequences <400 
bp were discarded and longer sequences were trimmed down to this length. 
The remaining sequences were clustered at a 97% identity threshold defining operational 
taxonomic units (OTU), according to the taxonomy of the SILVA 16S rRNA sequence 
database (www.arb-silva.de). Chimeric sequences, representing PCR and sequencing artifacts, 
were filtered out and discarded during this step.  
Whole transcriptome sequencing 
Library preparation for RNA-seq was performed using the TruSeq Stranded mRNA Sample 
Prep Kit (Illumina, Inc, California, USA). Total RNA samples (1 μg) were ribosome depleted 
and then reverse-transcribed into double-stranded cDNA with Actinomycin added during first-
strand synthesis. The cDNA samples were fragmented, end-repaired and polyadenylated before 
ligation of TruSeq adapters. The adapters contain the index for multiplexing. Fragments 
containing TruSeq adapters on both ends were selectively enriched with PCR. The quality and 
quantity of the enriched libraries were validated using Qubit® (1.0) Fluorometer and the 
Bioanalyzer 2100 (Agilent, Waldbronn, Germany). The product is a smear with an average 
fragment size of approximately 360 bp. The libraries were normalized to 10nM in Tris-Cl 10 
mM, pH 8.5 with 0.1% Tween 20.  
The TruSeq SR-/ TruSeq PE Cluster Kit v4-cBot-HS (Illumina, Inc, California, USA) was used 
for cluster generation using 8 pM of pooled normalized libraries on the cBOT. Sequencing was 
performed on the Illumina HiSeq 2500 paired end at 2x126 bp or single end 126 bp using the 
TruSeq SBS Kit v4-HS (Illumina, Inc, California, USA). Sequencing images were transformed 
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with Illumina Basecaller software to bcl files and demultiplexed to fastq files with CASAVA 
v1.8.2 software (Illumina).  
Quality check on the reads was performed with fastqc (v.0.10.0, Babraham Institute, 
Cambridge, UK). Raw sequencing reads were mapped to the Homo sapiens genome 
(GRCh38.p7 build) using RSEM (v1.2.12) 57 implementation of Bowtie software (v 1.0.0) 58 
alignment program with the Ensemble annotation (v 75). 
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6.2. Staphylococcus aureus enhances the tight junction barrier integrity in healthy 
nasal tissue, but not in nasal polyps 
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Capsule Summary 
Staphylococcus aureus infection increases the expression of the tight junctions (TJs) in 
healthy nasal tissue; while nasal polyps show decreased TJ expression at baseline and are 
unable to upregulate TJs to strengthen the epithelial barrier. 
Key words 
Staphylococcus aureus, epithelial barrier, tight junction, chronic rhinosinusitis 
To the Editor: 
Chronic rhinosinusitis (CRS) is characterized by mucosal inflammation of nasal and 
sinus cavities. Clinically relevant CRS phenotypes are defined by the presence (CRSwNP) or 
absence (CRSsNP) of nasal polyps (NPs). CRSwNP is mostly defined by a Th2 type 
microenvironment and eosinophilia, while CRSsNP rather involves Th1 responses and 
neutrophilia.1 Previous studies have associated Staphylococcus aureus (S. aureus) as one of the 
factors driving inflammation in NPs, but the relationship between the mucosal barrier and S. 
aureus remains to be investigated .2 
Tight junctions (TJs) represent transmembrane and adaptor proteins sealing the most 
apical part of intercellular junctions between adjacent epithelial cells. They regulate epithelial 
impermeability against pathogens and foreign particles, such as allergens. Members of the TJ 
proteins include the occludin, tricellulin and the claudin families that form homodimers and 
heterodimers between neighboring cells, forming the intercellular barrier. Junctional adhesion 
molecules (JAM), and the zonula occludens (ZO) proteins form the connection of 
transmembrane TJ molecules to the actin cytoskeleton. 3  
Defective expression of TJs and barrier leakiness has been reported in allergic disorders; 
such as asthma3, atopic dermatitis4 and CRS.5 TJs can be regulated by an inflammatory 
microenvironment in tissues; in CRS by cytokines such as IFN-γ and IL-4.5 Recently, TJs have 
also been shown to be regulated by TLR-9 ligands; such as CpG-DNA, leading to an increase 
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in TJ expression and epithelial barrier integrity.6 TJ genes respond to tissue factors and foreign 
factors to maintain epithelial integrity; however, the response of epithelial barrier molecules to 
common airway pathogens remains to be investigated. In this letter, we report that S. aureus 
enhances barrier function of healthy nasal epithelial cells by increasing the expression of TJ 
molecules. 
Nasal mucosa tissue explants of human inferior turbinate (IT) from healthy donors and 
NP tissue from CRSwNP patients (Table E1) were infected with S. aureus or Staphylococcus 
epidermidis (S. epidermidis) with a dose of 2x107 CFU/ml and observed for IL1ß and IL6 
response (Fig E1, A, B). S.epidermidis and S.aureus stimulated samples did not differ in terms 
of IL1ß and IL6 expression (Fig E1, C). Samples in which S. aureus was absent from initial 
explant tissue in both IT and NP donors was selected (Fig E2). Expression levels of 21 TJ and 
related molecules known to be constitutively expressed in nasal mucosa and airways were 
assessed with quantitative PCR (Table E2). We observed that upon S. aureus infection, there 
is an up-regulation of the expression of several TJ molecules, namely claudins -1, -3, -4, -7, -
10, ZO-3, occludin, tricellulin, cingulin, JAM-A, MARVELD3 and E-cadherin in IT samples 
within 24 hours, suggesting that the healthy nasal mucosal tissue responds adequately to protect 
itself against bacterial invasion. Claudin-10, ZO-3 and Occludin are upregulated 4.06, 2.06 and 
2.26-fold in S. aureus stimulated IT samples, respectively (Table E3). We also observed 
upregulation of Occludin, JAM-A, Cingulin to a lesser extent with S. epidermidis. Furthermore, 
MARVELD3 showed an upregulation of 2.19 fold, greater than that of S. aureus (1.25 fold) 
stimulated samples in response to S.epidermidis. Although it is not a strong pathogen as S. 
aureus, S epidermidis also contains innate immune response stimulating substances that may 
also affect barrier. In contrast, NP tissue shows a significant decrease of claudin-4, claudin-5, 
occludin and JAM-A expression after S. aureus infection, expressional changes were not 
observed for other TJ molecules. Likewise, decrease of expression of claudin-4, claudin-5, 
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occludin and JAM-A were observed after stimulation with S. epidermidis. Overall, stimulation 
of IT tissue with S. aureus or with S.epidermidis leads to upregulation of various TJ molecules; 
while the NP tissue shows no change or downregulation of barrier molecules in response to 
Staphylococcus species. (Fig 1, Fig E3). Claudins -11, -17, -20, CLDND1, JAM-3, MAGI-1, -
3 and ZO-1 were statistically not different in S. aureus and S. epidermidis infected tissue 
explants in both IT and NP tissue (Fig E3). Although it was not possible to perform Ussing 
chamber or macromolecule flux experiments in these tissue explants for a direct evidence of 
barrier integrity change, increased expression of TJ molecules may suggest an increased 
epithelial barrier, increased expression of TJ molecules may suggest an increased epithelial 
barrier. 
Table I. Clinical data of patients included in the study 
AERD: Aspirin exacerbated respiratory disease 
 
 
 
 
 
 
 
 
 Controls CRSwNP 
Number of patients 8 7 
Age, median (range) 45.1 53.8 
Gender, female/male 3/5 ¾ 
Atopy 0/8 4/7 
Asthma 0/8 4/7 
AERD 0/8 1/7 
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Figure E1. Protein measurement of (A) IL1B and (B) IL6 on inferior turbinate nasal tissue 
(n=3) supernatants stimulated with increasing doses of S. aureus. (C) mRNA expression of 
IL1B and IL6 in IT (n=11) tissue infected with S. aureus (2x107 CFU/ml) or S. epidermidis 
(2x107 CFU/ml). Gene expression measured by qRT-PCR. Expression values calculated as 
arbitrary units (2(-ΔCt)*1000), percentage of GAPDH expression. 
 
 
 
 
 
 
 
 
IL 1 B
%
 o
f 
G
A
P
D
H
 e
x
p
r
e
s
s
io
n
U
S
S
. 
e
p
id
e
rm
id
is
S
.a
u
re
u
s
0
5 0
1 0 0
1 5 0
IL 6
U
S
S
. 
e
p
id
e
rm
id
is
S
.a
u
re
u
s
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
C 
79 
 
 
 
 
 
 
 
 
 
 
Figure E2. Quantification of S.aureus abundance on inferior turbinate and nasal polyp tissue 
after initial stimulation dose of 2x107 CFU/ml. p-value<0.05 (*). 
Table II. Screened predesigned probes chosen from the Applied Biosystems database. 
Gene symbol Gene name Assay ID 
CDH1 E-cadherin Hs01023894_m1 
CGN Cingulin Hs00430426_m1 
CLDN1 Claudin-1 Hs00221623_m1 
CLDN3 Claudin-3 Hs00265816_m1 
CLDN4 Claudin-4 Hs00976831_m1 
CLDN5 Claudin-5 Hs00533949_m1 
CLDN7 Claudin-7 Hs00600772_m1 
CLDN10 Claudin-10 Hs00734479_m1 
CLDN11 Claudin-11 Hs00194440_m1 
CLDN17 Claudin-17 Hs01043467_s1 
CLDN20 Claudin-20 Hs01851239_s1 
CLDND1 Claudin-25 Hs00219886_m1 
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EGF Epidermal growth factor Hs01099999_m1 
F11R, JAM-A Junctional adhesion molecule 1 Hs00170991_m1 
INADL InaD-like Hs00195106_m1 
JAM3 Junctional adhesion molecule 3 Hs00230289_m1 
MAGI1 Membrane associated guanylate kinase, WW and PDZ domain 
containing 1 
Hs00191026_m1 
MAGI3 Membrane associated guanylate kinase, WW and PDZ domain 
containing 1 
Hs00326365_m1 
MARVELD2 MARVEL domain containing 2, Tricellulin Hs00376394_m1 
MARVELD3 MARVEL domain containing 3 Hs00369354_m1 
OCLN Occludin Hs00170162_m1 
PGK1 Phosphoglycerate kinase 1 Hs00943178_g1 
TJP1 Tight junction protein 1, Zonula occludens 1 Hs01551861_m1 
TJP3 Tight junction protein 3, Zonula occludens 3 Hs00274276_m1 
TMEM234 Transmembrane protein 1 Hs00963921_m1 
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Figure 1. S. aureus upregulates TJs and improves barrier integrity in inferior turbinates, but 
not in nasal polyps. (A) mRNA expression of TJ and junction associated molecules in IT (n=11) 
tissue infected with S. aureus (2x107 CFU/ml) (n=8) or S. epidermidis (2x107 CFU/ml) (n=3). 
(B) mRNA expression of TJ and junction associated molecules in NP (n=10) tissue infected 
with S. aureus (2x107 CFU/ml) (n=7) or S. epidermidis (2x107 CFU/ml) (n=3). TJ gene 
expression measured by qRT-PCR. Expression values calculated as arbitrary units (2(-
ΔCt)*1000), percentage of GAPDH expression. p-value<0.05 (*), p-value<0.01 (**) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
 
 
Figure E3 (A and B). mRNA expression of other TJ and related molecules in IT (n=11) and 
nasal NP (n=11) tissue infected with S. aureus (2x107 CFU/ml) or S. epidermidis (2x107 
CFU/ml). TJ gene expression measured by qRT-PCR. Expression values calculated as arbitrary 
units (2(-ΔCt)*1000), percentage of GAPDH expression. 
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Table III. Fold change of TJ gene expression in IT and NP tissue 
 
 
Next, we validated the observations seen on mRNA expression by staining claudin-4 and 
claudin-7 proteins with immunohistochemistry. Cryosections taken from ex vivo human nasal 
tissue infected with S. aureus were stained for the TJ molecules of the epithelial layer. Similar 
to the observations made for mRNA expressions, both claudin-4 and claudin-7 showed an 
increase in staining intensity in IT samples infected with S. aureus for 24 hours (Fig 2, A) and 
to a lesser extent, samples infected with S. epidermidis. In contrast, NP tissue showed a 
different expression profile of the TJs claudin-4 and claudin-7, at baseline and after infection. 
The epithelial layer was relatively intact and showed a low but uniform expression of both 
claudin-4 and claudin-7 in resting NP samples. However, we observed extensive epithelial 
shedding in NP samples infected with S. aureus and only basal and subepithelial cells remained 
intact. Claudin-4 and claudin-7 expression cannot be observed in the epithelial layer, 
implicating a role for S. aureus in the disrupted epithelial barrier of NP tissue (Fig 2, B). Such 
extensive epithelial layer shedding was not observed in NP tissue stimulated with S. 
 Inferior turbinate tissue Nasal polyp tissue 
Gene Name S. 
aureus 
vs US  
p-value 
S. 
aureus 
vs US  
Fold 
change 
S. 
epidermidis 
vs US 
p-value 
S. 
epidermidis 
vs US 
Fold change 
S. aureus vs US  
p-value 
S. 
aureus 
vs US  
Fold 
change 
S. 
epidermidis 
vs US 
p-value 
S. 
epidermidis 
vs US 
Fold change 
Claudin 1 0.0391 1.19 Ns 0.56 Ns -0.43 Ns -0.03 
Claudin 3 0.0391 1.43 Ns 0.32 Ns -0.48 Ns 0.41 
Claudin 4 0.0391 0.75 Ns 0.35 0.0031 -0.60 Ns -0.28 
Occludin 0.0078 2.26 0.022 1.24 0.0046 -0.62 0.007 -0.65 
JAM-A 0.0234 0.67 0.0391 0.68 0.0328 -0.44 0.007 -0.56 
Cingulin 0.0409 1.32 0.0386 0.91 Ns -0.10 Ns 0.20 
Claudin 7 0.0157 1.04 Ns -0.15 Ns -0.39 Ns -0.10 
Claudin 10 0.0078 4.06 Ns -0.37 Ns -0.24 Ns 0.14 
ZO 3 0.0078 2.06 Ns 0.53 Ns -0.46 Ns -0.29 
Tricellulin 0.0078 1.74 Ns 0.63 Ns -0.22 Ns -0.14 
MARVELD3 0.0156 1.25 0.011 2.19 Ns -0.35 Ns -0.01 
E-cadherin 0.0234 1.31 Ns 0.41 Ns -0.16 Ns -0.40 
Claudin 5 Ns -0.34 Ns -0.13 0.0046 -0.7 0.007 -0.73 
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epidermidis. Mean fluorescence intensities of 3 donors confirmed the changes in protein 
expression in both IT and NP samples (Fig 2, C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (A) Immunofluorescence stainings of human claudin-4 and -7 molecules in IT (n=3) 
tissue infected with S. aureus (2x107 CFU/ml) or S. epidermidis (2x107 CFU/ml) (n=3). (B) 
Immunofluorescence stainings of human claudin-4 and -7 molecules nasal tissue with NP (n=3) 
infected with S. aureus (2x107 CFU/ml) or S. epidermidis (2x107 CFU/ml) (n=3). (C) Mean 
fluorescence intensity values of claudin-4 and -7 in ITs and NPs (n=3). Measurements were 
taken from three separate epithelial regions of equal area from each donor. p-value<0.05 (*), 
p-value<0.01 (**), p-value<0.001 (***). 
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To assess the general state of tissue viability in tissues inoculated with S. aureus; we 
stained cryosections with TUNEL staining; using terminal deoxynucleotidyl transferase to 
label cleaved DNA molecules in tissue formed by activation of apoptotic signal cascades. In 
IT unstimulated samples and in samples infected with S. epidermidis fluorescence intensity of 
cleaved DNA was very low and comparable between unstimulated tissue and tissue infected 
with S. aureus; indicating that healthy nasal tissue did not undergo tissue damage in the 
presence of S. aureus and the increased expression in TJ molecules and increased barrier 
protecting the tissue is unrelated to tissue damage. In contrast, we observed severe tissue 
damage and shedding with apoptosis taking place in nasal polyps. (Fig E4).  
    S. aureus colonization of the nasal mucosa is linked to the success of surgical outcome in 
CRS patients.7 The amount of S. aureus colonization and intramucosal immune reaction is also 
shown to be directly contributing to disease severity in nasal polyps.8 Staphylococcal protein 
A was shown to induce IL-10 in CRSwNPs, possibly resulting in improved bacterial survival 
to further drive CRS pathogenesis.9 These findings; combined with our observations suggest 
that CRSwNPs are prime sites for S. aureus entry into the tissue, contributing to the 
pathogenesis of upper airway allergic diseases. Inherent dysbiosis in the nasal polyp epithelial 
barrier might contribute to the ability of S. aureus to penetrate the nasal tissues; and contact of 
S. aureus with immune cells may increase inflammatory cytokine production and contribute to 
persistence of inflammation in CRSwNP. Therapeutic mechanisms that specifically block 
bacterial proteolytic enzymes may contribute to the management of CRSwNP, through 
preservation of the tenuous epithelial barrier. The present study provides evidence for a 
strengthened barrier function in nasal epithelium in response to S. aureus in healthy nasal 
tissue. This effect can also be observed with a commensal bacterium of the nasal mucosa, S. 
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epidermidis that also contains innate immune response stimulating substances that may also 
affect epithelial barrier to a lesser extent. In contrast, we demonstrated in an in vitro setting that 
the epithelial barrier has been disrupted in nasal polyps of CRSwNP patients, and might be 
unable to correctly remodel in CRS patients’ due to extensive epithelial damage and shedding 
induced by S. aureus. 
 
Figure E4. Immunofluorescence staining of TUNEL in IT tissue and NP tissue; infected with 
S. aureus (2x107 CFU/ml) or S. epidermidis (2x107 CFU/ml). 
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Supplementary Material 
Staphylococcus aureus enhances the tight junction barrier integrity in healthy nasal 
tissue, but not in nasal polyps 
Methods 
Tissue culture and infection experiments 
Patients. Nasal tissue was obtained from 7 CRSwNP patients and 8 control patients at the 
department of Oto-Rhino-Laryngology, Ghent University Hospital. None of the patients had 
taken oral corticosteroids or antibiotics 4 weeks and topical corticosteroids 2 weeks. The 
diagnosis of CRSwNP was made according to European Position Paper on Rhinosinusitis and 
Nasal polyps (EPOS) 2012 guideline. The inferior turbinate (IT) of patients with septal 
deviation were used as controls. The clinical data of all the patients were shown in Table I. 
Informed consent was obtained from all patients before sample collection. The ethics 
committees of the Ghent University Hospital approved the study.   
Preparation of S. aureus stocks. S. aureus RN6390, containing the plasmid pALC1743, a 
pSK236-derived shuttle plasmid carrying an active S. aureus promoter (RNAIII promoter), was 
chosen as infection strain in this study. In particular, this strain does not produce S. aureus 
enterotoxins such as: enterotoxin A, B, C, E, and toxic shock syndrome toxin 1 (TSST-1). The 
concentration of S. aureus 2×107 CFU/well was chosen according to the former ex vivo 
experiments that we used bacterial concentrations of 107– 108 CFU/ml and prepared pilot 
experiments to finally choose a concentration of 2x107 CFU/ml as sub-optimal effective dose, 
which did not overgrow the mucosa. 
Ex vivo human nasal mucosa infection model. CRSwNP and control tissues were washed 
three times by tissue culture medium (TCM) (RPMI1640: DMEM=1:1) with antibiotics (50 
IU/ml penicillin (Invitrogen, Belgium) and 50 µg/ml streptomycin (Invitrogen, Belgium). The 
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washed tissue explant was cut into 24 small cubes approximately 25 mm2 in size for further 
investigation. Each cube was placed on a mesh in a 6-well plate with 2.5ml TCM supplemented 
with antibiotics in each well to create an air liquid interface. All tissue cubes were incubated at 
37°C in humidified air with 5% CO2 overnight, and then transferred the tissue cubes to a 24-
well tissue culture plate (Falcon, BD Biosciences, Belgium), infected separately with 2ml 
inoculum containing 2×107 CFU S. aureus and 2ml TCM. 
mRNA isolation and reverse transcription. RNA from nasal tissue samples was isolated 
using Rneasy Mini Kit and RNase-free DNase (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. cDNA was obtained from RNA samples via reverse transcription 
using the RevertAid RT kit and random hexamers (Thermofisher Scientific, Massachusetts, 
USA) as described by the manufacturer.  
mRNA analysis by Taqman array microfluidic cards.  Real time quantitative PCR was 
performed using the Taq-man array micro fluidic cards (Applied Biosystems, California, USA) 
using 25 predesigned probes including junctional molecules expressed in epithelial cells, 
chosen from the Applied Biosystems database (Table II), were screened. The probes were 
selected as spanning exon-exon junctions of each gene and having an amplicon length of 200bp 
maximum. A total cDNA amount of 400ng per sample was mixed with the TaqMan Gene 
Expression Master Mix (Applied Biosystems) added to the microfluidic card. The cards were 
run on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Arbitrary units for each 
gene were calculated according to the 2(-Δct) x 1000 formula. Out of 25 genes, 21 that were 
found to be expressed in nasal mucosa tissue were quantified for further analysis. 
Immunofluorescence staining of TJs 
Cryosections taken from nasal tissue samples of ex vivo human nasal mucosa infection model 
were fixed with 4% paraformaldehyde (Fluka, Sigma-Aldrich), permeabilized and blocked 
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with PBS with 0.1% Triton-X (Acros Organics, Gell, Belgium) and 10% goat serum (Dako, 
Denmark). After washing samples with PBS containing 0.1% Triton-X, they were incubated 
with rabbit anti-claudin-7 (Life Technologies, USA) at room temperature for 60 minutes and 
goat anti-rabbit antibody labelled with Alexa fluor 546 dye (Life Technologies, USA) at room 
temperature for 45 minutes. Alternatively; the cryosections were incubated with mouse anti-
claudin-4 (Life Technologies, USA) at room temperature for 60 minutes and rabbit anti-mouse 
antibody labelled with Alexa fluor 546 dye (Life Technologies, USA) under the same 
conditions for 45 minutes. The nuclei were stained with diluted Hoechst 33342 (Life 
Technologies, USA) dye at room temperature for 15 minutes. The slides were then mounted 
with “Prolong Gold Antifade” mounting medium without DAPI (Life Technologies, USA). 
Sections were examined with a confocal microscope (Leica TCS SPE, Leica Microsystems, 
Heerbrugg, Switzerland). Data were analysed and fluorescence intensity was quantified using 
Image J software, by selecting three regions of equal area from each donor. 1 
TUNEL staining 
TUNEL staining of nasal tissue samples were performed with the click-it TUNEL Alexa fluor 
647 imaging assay kit (Life Technologies, USA) as described by the manufacturer. The nuclei 
were stained with diluted Hoechst 33342 dye (Life Technologies, USA) at room temperature 
for 15 minutes. Sections were examined with a confocal microscope (Leica TCS SPE, Leica 
Microsystems, Heerbrugg, Switzerland). 
Statistics All data analysis was performed using GraphPad Prism version 6.01 (GraphPad 
Software, San Diego California, USA). For comparison of experiments run in parallel, a 
Wilcoxon matched pairs test was applied. All data are presented as mean ± standard deviation. 
P values <0.05: *, <0.01: ** and <0.001: *** are indicated inside the graphs. 
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7. General Discussion 
7.1. Is downregulation of barrier genes the only sign of barrier loss? 
In the studies we have performed, we had the chance to perform high throughput analysis of 
the transcriptome from tissue biopsies and explants of a small variety of allergic diseases of 
skin and nasal airways. While there are differences between expression of particular molecules 
specific to one tissue or another, we made the observation that connects these allergic diseases 
together. The cellular junctions, in particular the adhesion molecules and TJs are among the 
most significantly changing molecules, and the majority of them are downregulated molecules 
in the lesional skin of AD skin compared to non-lesional skin or healthy skin.  
Similarly, nasal polyps of CRS patients display a lower expression value for TJ molecules 
compared to inferior turbinate nasal tissue of healthy subjects. The same observation is 
repeated in allergic contact dermatitis as well, where we observed a significant downregulation 
of TJ and SC in severe allergic skin exposed to PPD, in comparison to mild allergic patients 
and skin from non-responding subjects.  
However, what is represented as barrier dysregulation might be more complex and depend on 
more factors than simple downregulation of barrier molecules in inflammatory lesions. Barrier 
molecules are known to be represented as five distinct gene families sharing similar function 
in the human genome: TJs, SC-associated molecules, adherens junctions, desmosomes and gap 
junctions. We have observed that the expression pattern of these 5 gene families do not always 
change in the same direction. TJ molecules specific to the skin, such as CLDN1, CLDN8 or 
CLDN10, or TJs expressed at a high level in human skin, but not specific only to skin such as 
CLDN4, CLDN5 and OCLN are observed to be downregulated in lesional AD skin. Some of 
these TJ molecules are also expressed at a lower level in non-lesional AD skin in comparison 
to healthy human skin. We think that these TJ molecules expressed at high levels in healthy 
skin, but downregulated in lesional AD skin represent the barrier defect component of AD. 
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However, when the whole TJ set of molecules are analyzed in AD, we observed that there is a 
set of TJ genes not expressed at all or expressed in very low levels in healthy human skin, but 
these TJ genes are actually upregulated when a lesion is developed. These genes include 
CLDN12, CLDN14, CLDN15, CLDN17 and CLDN22 which are known to be expressed in 
endocrine tissues and kidneys. These genes are upregulated in lesional AD tissue, but their 
expression levels do not reach to that of major skin TJ molecules such as CLDN1 or CLDN4. 
Currently the cause for the upregulation of genes in lesional skin normally not expressed in 
healthy skin is not known, but it is possible that a redundancy mechanism exists in the 
activation of barrier genes. Inflammation and infiltration of skin by lymphocytes lead to tissue 
damage and loss of major barrier genes, but in response to inflammation these “minor” TJ 
genes might activate to preserve tissue structure and attempt to control the lesion from 
spreading further. In addition, tissue repair mechanisms immediately activate at the time of 
damage and genes that are expressed at very low levels might be upregulated during tissue 
recovery and keratinocyte proliferation. 
This pattern of upregulation of normally not expressed genes in lesional AD is repeated in other 
cell-cell junction molecule families. In the SC layer involucrin (IVL) is observed to be 
significantly upregulated in lesional skin, as well as keratin family molecules described to be 
specific to oral and esophageal mucosa, such as KRT6A, KRT6B and KRT6C. For gap 
junctions; molecules such as GJB2, GJB6 and GJC1 are upregulated to very high levels in 
lesional AD skin. For desmosome, molecules such as desmocollin 1 (DSC1), desmoglein 1 
(DSG1) and desmoglein 3 (DSG3) are upregulated when a lesion develops. Adherens junction 
molecules show the same pattern with the upregulation of CDH1 and CDH3.  
At the moment; the precise function of these molecules and the exact cause for their increased 
expression is unknown. More studies should be performed to understand if they possess sealing 
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function for the epidermal barrier, or if this observation is a redundancy mechanism to preserve 
skin structure.  
7.2. Is S. aureus colonization one of the starting events of an AD lesion formation? 
By collecting skin swabs from AD patients matched with the samples analyzed with RNA-
sequencing, we aimed to link skin transcriptome with microbiome. Furthermore, our idea of 
co-sequencing skin transcriptome and skin microbiome from AD patients gave us the unique 
opportunity to perform “meta-data” analysis on the two different -omics data-sets we acquired 
from matched patients.  
Our analysis of the AD skin microbiome uncovered significant increase in S. aureus frequency 
in the lesional and non-lesional skin of AD samples in comparison to healthy skin.  
We then aimed to uncover the reasons for this increase in S. aureus abundance in the 
transcriptomic signature of AD skin. We proposed two conflicting hypotheses: S. aureus 
colonization of non-lesional human skin might result in activation of innate immunity pathways 
and trigger the infiltration of colonization sites with pro-inflammatory lymphocytes, thus 
paving the way for barrier disruption, opening of the skin barrier to allergens, and establishment 
of the chronic inflammatory cycle for the AD lesion. This hypothesis proposes S. aureus 
presence on the skin as one of the initiating factors of AD lesion development. The second 
hypothesis gives the increase in S. aureus abundance as a result of the lesion formation. S. 
aureus, being an opportunistic pathogen, takes advantage of the unique inflammatory and 
transcriptomic signature. 
To find evidence for these hypothesis, we performed correlation calculations of S. aureus 
frequency in significantly regulated sets of genes in AD transcriptome. We correlated all 5 
families of cell-cell junctions with the S. aureus abundance in lesional skin. The only 
significant correlations found were in 4 TJ genes: CLDN4, CLDN5, TJP1 (ZO-1) and TJP2 
(ZO-2). These genes correlate negatively in lesional AD skin with S. aureus abundance, and 
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correlate positively with several other commensal Staphylococcus species, such as S. 
epidermidis, S. hominis, S haemolyticus and S. caprae.  
The findings led us to suggest that the second hypothesis, S. aureus colonization being one of 
the consequences of lesion formation to be close to reality. The first indication is the number 
of genes correlating significantly with S. aureus. If S. aureus colonization is one of the main 
factors behind lesion development and barrier loss, we would expect negative correlations on 
multiple levels of skin barrier, such as in SC molecules or adherens junctions, in addition to 
TJs. We would also expect S. aureus colonization to regulate expression levels of other highly 
expressed TJ molecules, such as CLDN1, or OCLN.  
Another point is the location of interaction between S. aureus and TJ molecule expression. We 
have observed significant correlations only in lesional AD skin, but not in healthy skin or non-
lesional AD skin. We observed 20%-70% S. aureus frequency in non-lesional AD skin, yet this 
frequency does not show the same correlations with CLDN4, CLDN5, TJP1 and TJP2 similar 
to lesional skin. We would expect S. aureus to have the same negative correlations in non-
lesional AD skin as well if the bacterial pathogen was one of the main factors behind lesion 
development. The results suggest to us that S. aureus takes opportunity of the downregulation 
of a few select TJ genes to colonize AD skin, and the downregulation of the barrier genes is 
tied to internal tissue factors and inflammation. 
Further studies are needed to confirm the interactions between CLDN4, CLDN5, TJP1 and 
TJP2; especially in the form of in vitro co-cultures of AD skin keratinocytes with S. aureus 
isolates from AD patients. Increasing the number of microbiome and transcriptome sequenced 
matched AD samples would also increase the power of correlation studies to result in more 
gene candidates. 
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7.3.Is the healthy epithelial tissue capable of responding to threats by strengthening 
barrier? 
One of the more interesting observations about the interactions between mucosal microbiota 
and barrier gene expression comes from our study on chronic rhinosinusitis. We included 
inferior turbinate tissue explants from healthy patients as a control for our stimulation of nasal 
polyp tissue stimulations with S. aureus. However; as a result of S. aureus stimulation, we 
observed significant upregulations of TJ molecules on healthy inferior turbinate tissue. This 
was opposed to the effect on nasal polyps taken from CRS patients, where we observed 
significant dowregulation of TJ molecules such as CLDN4, CLDN5, OCLN and JAM-A and 
the rest of the analyzed molecules did not change in response to S. aureus. Confocal 
microscopy of CLDN4 and CLDN7 stainings on inferior turbinate tissue confirmed protein 
upregulation after S. aureus stimulation. 
During the revision process we were able to confirm our findings by performing the same 
stimulation experiments on in vivo explant tissue with a commensal of skin and nasal tissue, S. 
epidermidis. With the S.epidermidis stimulation, we received a mixed tissue response. We 
observed an upregulation of several TJ molecules, such as OCLN, JAM-A, Cingulin and 
MARVELD3, but not to the same extent observed in response to S. aureus. 
This leads us to conclude that healthy nasal epithelium is capable of responding to pathogens 
by upregulating the expression of barrier molecules, but this response is not specific to threats 
like S. aureus. Commensal bacteria of the mucosa also result in a response of diminished effect. 
However, we see the loss of this response in CRS nasal polyp tissue, along with thinning of the 
nasal epithelial layer, and extensive epithelial shedding and cell death after S. aureus 
stimulation. These results give more credence to our second hypothesis of bacterial 
colonization in allergic diseases: The barrier is already disrupted in lesional AD skin or CRS 
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nasal polyps, and the pathogens like S. aureus have opportunistic functions to take advantage 
of disrupted mucosa to grow exponentially. 
7.4. What does immune tolerance to allergens mean in terms of epidermal barrier? 
Our third study allowed us to monitor lesion development in allergic contact dermatitis in a 
short term controlled manner. We applied PPD-infused vaseline containing patches to back-
skin of PPD allergic hairdressers, while also including hairdressers with long-term exposure to 
PPD, but non-responding to the allergen. The patch was kept on skin for 2 days, and skin 
biopsies were taken from the PPD stimulated area after 4 days. This study allowed us to grade 
and sequester our sample pool according to clinical severity of inflammation. This way, we 
were able to observe the transcriptomic changes in non-responders, mild and severe allergic 
individuals. PCA analysis showed that the transcriptome of PPD exposed non-responder skin 
tissue is markedly different from PPD exposed severe and mild allergic skin. 
Our pathway analysis revealed that cadherin signaling molecules as well as adhesion molecules 
were among the most significantly downregulated gene-families in severe allergic PPD 
exposed skin in comparison to vaseline controls. While in itself this is to be expected, we aimed 
to also analyze barrier molecules in non-responders and mild allergic skin to document the state 
of epidermal barrier in non-responder individuals. 
An interesting observation we made is that the large-scale downregulation of TJ molecules and 
SC molecules are constrained to the severe allergic individuals. While there are patterns 
towards downregulation in mild allergic skin, these were not found to be significant. Overall, 
in non-responders, mild and severe allergic skin have similar expression levels for most barrier 
molecules before PPD exposure. This leads us to conclude that in allergic contact dermatitis 
there is no inherent barrier disruption without the presence of allergen and accompanying 
inflammation. This observation is in contrast to AD, where we see downregulation of several 
important TJ molecules such as OCLN, CLDN1 and CLDN4 in non-lesional skin of allergic 
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individuals in comparison to healthy skin. We suggest that the inherent loss of barrier in AD 
patients might be due to long term exposure to more commonly encountered allergens, such as 
house dust mite, or grass pollen. Whereas in allergic contact dermatitis, exposure to allergens 
is often occupational and restricted to certain locations of the body. 
7.5. Conclusion 
In conclusion, this thesis demonstrates essential findings on skin and mucosal barrier 
regulation. First, epithelial barrier increases and strengthens itself against infectious agents 
such as S. aureus. Second, the barrier is downregulated if there is a sub-epidermal inflammation 
in skin. During lesion formation certain barrier molecules that are not expressed in resting 
conditions are upregulated together with tissue recovery and cell proliferation. Third, T-cell 
responses to external antigens such as PPD in hairdressers cause tissue destruction and a strong 
barrier damage which may be used as a mode for immune tolerance modulation to prevent 
epithelial barrier dysregulation in occupational contact dermatitis. 
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